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ABBREVIATIONS 
A23187, ca2+ ionophore 
cAMP, 5'-cyclic adenosine monophosphate 
cGMP, 5'-cyclic guanosine monophosphate 
dBcAMP, dibutyryl 5'-cyclic adenosine monophosphate 
dBcGMP, dibutyryl 5'-cyclic guanosine monophosphate 
DMSO, dimethyl sulfoxide 
DNSA, dimethylamino-naphthaline-5-sulfonamide 
i.v., intravenous 
m1 and m2-cholinoceptor, m1 and m2 muscarinic receptors 
n-cholinoceptors, nicotinic receptors 
NS, not significant 
PGE2 , prostaglandin E2 
PGF2 a, prostaglandin F2 a 
PKA, protein kinase A 
PKC, protein kinase c 
TPA, tetradecanoyl-phorbol-acetate 
VIP, vasoactive intestinal polypeptide. 
[D-p-Cl-Phe6,Leu17]-VIP, competitive antagonist at VIP 
receptor 
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NOTE ON TERMINOLOGY: The word "agonist" is used for 
simplicity for all stimulants of bicarbonate secretion, 
although it is realized that the longer term "secretory 
stimulant" is more accurate, since some "agonists," like the 
cyclic nucleotides, do not have cell membrane receptors. 
ABSTRACT 
The present research studied the regulation of duodenal 
bicarbonate secretion in the anaesthetized guinea-pig, using 
a model that permitted the study of active transport of 
bicarbonate. 
It was determined that dibutyryl 3' ,5'-cyclic adenosine 
monophosphate, vasoactive intestinal polypeptide, 
prostaglandin E2, carbachol and theophylline are the chief 
agonists of duodenal bicarbonate secretion. Vasoactive 
intestinal polypeptide and prostaglandin E2 act directly via 
distinct receptors on the duodenal enterocytes, activating 
adenylate cyclase and protein kinase A in sequence to 
initiate bicarbonate secretion. 
In addition, there is good evidence that the inositol 
phospholipid and protein kinase C cascade is also involved, 
possibly to a lesser extent, since tetradecanoyl-phorbol-
acetate and prostaglandin F2a were agonists of bicarbonate 
secretion. 
Carbachol, using a m-cholinoceptor pathway, stimulates 
duodenal bicarbonate secretion by releasing vasoactive 
intestinal polypeptide. Consistent with this finding is the 
observation that carbachol has no receptors on duodenal 
enterocytes. The role of the nicotinic pathway in 
bicarbonate secretion, however, remains uncertain. 
Duodenal bicarbonate secretion can be inhibited by 
somatostatin and acetazolamide. Somatostatin selectively 
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suppresses carbachol-stimulated and VIP-stimulated duodenal 
bicarbonate secretion, but not PGE2-stimulated bicarbonate 
secretion. Receptors for somatostatin coupled to adenylate 
cyclase could not be detected on isolated duodenal 
enterocytes, which strengthens the hypothesis that carbachol 
does not act directly on these epithelial cells, but via a 
second transmitter, vasoactive intestinal polypeptide. 
Carbonic anhydrase activity is necessary for secretion 
of bicarbonate, since acetazolamide-inhibition of this 
enzyme decreased bicarbonate secretion, both basal and 
stimulated by many different agonists. Carbonic anhydrase 
serves as a common final step in the generation of 
bicarbonate in duodenal enterocytes. This enzyme was located 
in the cytoplasm of cells in the villus as well as the crypt 
cells, implying that bicarbonate secretion occurs along the 
length of the villus and crypt. 
In summary, the present research has shown direct 
stimulation of duodenal bicarbonate secretion by vasoactive 
intestinal polypeptide, which participates also in them-
cholinergic pathway, and by prostaglandin E2. Adenylate 
cyclase and protein kinase A appear to be the intracellular 
messengers with the primary function of initiating duodenal 
bicarbonate secretion. However, there is convincing evidence 
that the inositol phospholipid and protein kinase C cascade 
also activates this secretion. Somatostatin selectively 
stops duodenal bicarbonate secretion. Carbonic anhydrase 
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activity in the crypt and villus is required as the final 
common step in bicarbonate production. 
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OBJECTIVES OF THE RESEARCH 
1. to set up and validate the methodology required for the 
study of active bicarbonate secretion in the guinea-pig 
duodenum in vivo 
2. to determine and compare the dose-response relationships 
of the chief agonists of duodenal bicarbonate secretion 
3. to define in detail the nature of the PGE2, VIP and 
cholinergic pathways that activate duodenal bicarbonate 
secretion 
4. to correlate the information obtained about 
extracellular factors regulating duodenal bicarbonate 
secretion with their corresponding intracellular messenger 
systems 
5. to examine the inhibitory effects of somatostatin-14 
peptide in relation to the PGE2, VIP and cholinergic pathways 
that activate duodenal bicarbonate secretion 
6. to examine the effect of inhibition (by acetazolamide) 
of carbonic anhydrase on the PGE2, VIP, cholinergic and other 
pathways that stimulate duodenal bicarbonate secretion 
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INTRODUCTION 
1. MUCOSAL BICARBONATE SECRETION AS A PHYSIOLOGICAL 
DEFENCE MECHANISM AGAINST PEPTIC ULCERATION IN THE PROXIMAL 
DUODENUM (THE DUODENAL BULB) 
When the stomach empties after a meal, gastric acid 
enters the proximal duodenum and reduces the intraluminal pH 
rapidly to< 3. It is necessary that this acid load be 
neutralized in order .that digestion will proceed normally. 
This function is served by bicarbonate secreted from the 
pancreas and the liver (into pancreatic juice and bile 
respectively). 
There is however another function of bicarbonate in the 
duodenum, which is, to prevent gastric acid and pepsin from 
causing peptic ulceration of the duodenal mucosa. The 
duodenal mucosa is now known to secrete an alkaline fluid 
containing NaHC03; there is no hard evidence that Brunner's 
glands produce bicarbonate (Flemstrom 1987). Based on a body 
of experimental observations, it is hypothesized that the 
function of duodenal mucosal bicarbonate secretion is to 
alkalinize the unstirred mucous layer adherent to the 
mucosal epithelium and thus prevent penetration of acid. 
This idea was proposed by Kivilaakso & Flemstrom (1984). It 
follows then that marked deficiency of bicarbonate 
production in the duodenal bulb mucosa would allow 
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hydrochloric acid and pepsin to reach and destroy the 
mucosal epithelial cells and penetrate deeply into the 
lamina propria and beyond, to cause true peptic ulceration 
(Isenberg et al. 1991). 
Several important experimental studies in normal men 
and women, and in persons with active and healed duodenal 
ulcers, provide compelling evidence in support of the 
hypothesis outlined here. These are reviewed briefly. 
Patients with duodenal ulcers secrete less bicarbonate from 
the duodenal bulb than normal persons in the basal (fasting) 
state as well as during duodenal lumen acidification 
(Isenberg et al. 19B7, Hogan & Isenberg 1991). This 
deficiency of bicarbonate output is noted, too, when the 
ulcer disease is in remission and the duodenal bulb mucosa 
appears to be completely normal at endoscopy and by 
histological examination (Basuk et al. 1989). This 
abnormality of bicarbonate secretion appears to be related 
to defective synthesis or release of mucosal PGE2 in 
duodenal ulcer patients (Bukhave et al. 1990, Hogan et al. 
1990). Hydrochloric acid stimulates duodenal bicarbonate 
secretion; this secretion is reduced to basal values by 
indomethacin, which diminishes endogenous production of 
prostaglandins by the duodenum (Isenberg et al. 1985). Most 
interestingly, cigarette smokers, who have a clearly higher 
rate of chronic, recurrent duodenal ulcer disease, are found 
to have diminished basal as well as hydrochloric acid-
15 
stimulated duodenal bicarbonate secretion (Isenberg et al. 
1987, Hogan & Isenberg 1991). 
One animal study also provides corroborative evidence 
for the hypothesis given above. In a classical rat model, 
cysteamine induced duodenal ulceration, which has some 
resemblance to human duodenal ulcer disease, is associated 
with strikingly reduced duodenal bicarbonate secretion (Stiel 
et al. 1983). It is interesting that only man and the horse 
Eguus caballus are afflicted by chronic duodenal ulcer 
disease (Isenberg & Hogan, 1990). Abnormalities of 
bicarbonate production have hitherto been documented only in 
human subjects with duodenal ulcers, and not in animals. 
The duodenal bulb is that region of the duodenum which 
is exposed to the lowest intraluminal pH. Of note, it is this 
organ which is particularly vulnerable to peptic ulceration. 
It is therefore not surprising that the duodenal bulb 
secretes very much more bicarbonate than the distal duodenum 
and jejunum, as shown in the rat (Isenberg et al. 1983) and 
confirmed in man (Isenberg et al. 1986). 
In this thesis, bicarbonate secretion, directed against 
acid and pepsin from the stomach, is examined in a specific 
animal model. Other mechanisms that cause ulcers (which 
include Helicobacter pylori, genetic abnormalities, 
hypergastrinaemia and nicotine), and additional factors that 
protect the duodenum (mucus secreted by duodenal mucosa! 
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cells and Brunner's glands, antero- and retrograde duodenal 
motility, etc.) are not examined here. 
2. EXTRACELLULAR CONTROL OF DUODENAL BICARBONATE SECRETION 
BY GASTROINTESTINAL PEPTIDE HORMONES AND PROSTAGLANDINS 
Duodenal bicarbonate secretion was likely to be a 
receptor-mediated event involving intracellular second 
messenger cascades. 
Studies in the bullfrog, rat, guinea-pig, rabbit, cat, 
dog and man, in vivo and in vitro, showed that duodenal 
bicarbonate secretion is stimulated by prostaglandins E and 
F, and the hormones VIP and glucagon, as well as several 
other compounds (Table 1). 
In addition, there is also a strong and very important 
element of autonomic neural control of bicarbonate secretion, 
parasympathetic as well as sympathetic (Fandriks et al. 
1991); cholinergic regulation is considered in detail below. 
The most potent agonist of duodenal bicarbonate 
secretion in mammals, including man, is hydrochloric acid, as 
shown in a number of studies where HCl was instilled 
intraluminally in the duodenum at a concentration up to 150 
rrunol/1 (Flemstrom et al. 1982a, Isenberg et al. 1985, 
Isenberg et al. 1985). It should be appreciated that 
intraluminal acid is the natural stimulus to duodenal 
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TABLE 1. Bicarbonate secretion by the duodenal surface 
epithelium (partial list). Some of the described effects are 
species-specific or are controversial. 
Stimulants: 
dBcAMP, arachidonic acid, beta-endorphin, carbachol, 
enkephalins, gastric inhibitory polypeptide, morphine, 
neurotensin, norepinephrine, pancreatic glucagon, 
prostaglandins: E1 , E2 , F2a, theophylline, vasoactive 
intestinal polypeptide. 
Inhibitors: 
acetazolamide, anoxia, clonidine, cyanide, ouabain. 
No effect: 
carbachol, dBcGMP, gastrin, insulin, secretin, serotonin, 
substance P, urogastrone. 
(from references: Algazi et al. 1989, Ballesteros et al. 
1991, Fandriks et al. 1986, Fandriks et al. 1991, Flemstrom 
& Turnberg 1984, Flemstrom et al. 1993, Garner et al. 1990, 
Granstam et al. 1987, Hogan et al. 1991, Hurst et al. 1982, 
Isenberg et al. 1985, Isenberg & Hogan 1990, Knutson et al. 
1992, Konturek et al. 1987, Lenz et al. 1989, Odes et al. in 
press, Safsten & Flemstrom 1986, Simson et al. 1981a, Simson 
et al. 1981b, Smedfors & Johansson 1986, Takeuchi et al. 
1990) 
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bicarbonate secretion; the pH threshold for duodenal 
bicarbonate secretion in humans was investigated and found 
to be 3.0 (Feitelberg et al. 1992). 
Acid-stimulated duodenal bicarbonate secretion was 
shown to be associated with the release of PGE2 into the 
duodenal tissue and duodenal lumen, and this bicarbonate 
secretion was markedly reduced by pre-treatment with 
indomethacin (Isenberg et al. 1986, Selling et al. 1987). 
HCl-stimulated duodenal bicarbonate secretion also involves 
the release of the hormone VIP (Smedfors et al. 1987). 
Stimulation by VIP mimics HCl-induced bicarbonate secretion 
(Wolosin et al. 1989). Therefore, from these studies it 
appeared that certain prostaglandins, notably PGE2 , and 
hormones, in particular the neuropeptide VIP, play a 
critical role in the regulation of duodenal bicarbonate 
secretion following stimulation by HCl. How PGE2 and VIP 
actually work was not clear. How other agonists work was 
also uncertain. It was not clear that all reputed agonists 
were really that. Therefore, while the extracellular 
regulation of bicarbonate secretion by the duodenal mucosa 
was well described, it was nonetheless incompletely 
understood. 
There were problems with many studies in the 
literature. Passive diffusion of bicarbonate from the blood 
to the duodenal lumen was not distinguished from active 
transport of this anion. The blood-to-lumen gradient for 
bicarbonate in most experiments, where the duodenal 
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perfusate contained 154 mmol/1 NaCl, was estimated as being 
approximately 25 : 1 (Isenberg & Hogan 1990). This shows 
therefore that "active" secretory phenomena were not being 
measured specifically. This does not mean, of course, that 
active secretion did not occur; it simply implies that this 
question was not being addressed. Of note, there was a 
strong "contrary" view that most bicarbonate "secretion" was 
really diffusion (Vattay et al. 1988). 
Also, there was little clarity about the relative 
potency of the identified agonists of bicarbonate secretion, 
since different species were used (and species-differences 
were observed), and experimental conditions varied 
considerably. The multitude of agonists somewhat clouded the 
picture of what the true physiological agonists were likely 
to be. 
3. INTRACELLULAR SIGNALLING MECHANISMS OF GASTROINTESTINAL 
PEPTIDE HORMONES AND PROSTAGLANDINS 
The intracellular signalling mechanisms related to PGE2 
and VIP, as well as other reputed agonists, were little 
studied. Little was known about whether the described 
actions of the agonists were receptor-related events. 
In early studies by Simson et al. (1981b), cAMP was 
suggested to act as a second messenger in bicarbonate 
secretion by frog duodenum in the Ussing chamber, since this 
secretion could be elicited by receptor-independent 
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adenylate cyclase activators like forskolin, by cAMP 
analogues and by theophylline. This fitted in nicely with 
data about the mode of action of PGE2 and certain peptide 
hormones, like VIP, in other parts of the gastrointestinal 
tract (Smith et al. 1990). A postulated role for cAMP as a 
second messenger was confirmed more recently by Dunk et al. 
(1989), Garner et al. (1990) and Yao et al. (1993). 
Knowledge concerning calcium as an intracelllular 
mediator of bicarbonate secretion was more speculative, 
since cholinergic stimulation did not appear to activate 
bicarbonate secretion in most species tested (Flernstrom et 
al. 1985, Takeuchi et al. 1990; see section on cholinergic 
regulation below). 
In interpreting the data from studies of intracellular 
messengers in the literature, therefore, there remained 
several unclear issues, which are addressed here in this 
thesis. 
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Approach to these issues: 
A series of experiments was designed to address the 
controversies described in this section of the research. 
Studies of bicarbonate secretion were performed in the 
isolated, perfused proximal duodenum of the guinea-pig in 
vivo. 
To begin with, compounds which activate the adenylate 
cyclase/cAMP/PKA and the inositol phospholipid/PKC cascades 
were tested in vivo under conditions of active (uphill) 
bicarbonate secretion. This was needed to obtain dose-
response data to show the relative potency of the agonists 
of bicarbonate secretion, and also indicated which 
intracellular messengers were likely to be operative in the 
process of bicarbonate secretion. 
Based on this information, selected doses of these 
agonists were next administered in combination in order to 
obtain further information relating to the intracellular 
mediators of bicarbonate transport. 
These studies in the guinea-pig in vivo were then 
complemented by certain experiments in isolated duodenal 
enterocytes in vitro where, for example, the response of 
adenylate cyclase and protein kinase A was measured in 
homogenates of duodenal enterocytes during exposure to the 
same agonists used in vivo. This enabled the in vivo data to 
be correlated with the results from the in vitro studies. 
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The in vitro studies were performed in a collaborative 
project (see Acknowledgements) and are important for 
understanding the meaning of certain of the in vivo results. 
4. CHOLINERGIC REGULATION OF DUODENAL BICARBONATE 
SECRETION 
As indicated above, neural regulation of bicarbonate 
secretion is very important. The cholinergic system is 
stimulatory and the sympathetics are inhibitory, in general 
(Flemstrom 1987, Fandriks et al. 1991). In this work, the 
cholinergic system alone is investigated. 
There are several studies that indicate that vagal 
stimulation, whether electrical (Granstam et al. 1987, 
Nylander et al. 1987), drug-induced (Lenz et al. 1989, 
Safsten & Flemstrom 1986) or by sham feeding (Ballesteros et 
al. 1991, Konturek & Thor 1987), promptly induces duodenal 
bicarbonate secretion in animals and in man. 
It was therefore expected that this action can be 
mimicked by m-cholinoceptor (muscarinic receptor) agonists, 
and that this would provide a sound laboratory tool for 
studies of this regulation. However, experimental 
cholinergic manipulation of bicarbonate secretion in 
different species has produced the most conflicting data. 
Carbachol, which acts on m-cholinoceptors and n-
cholinoceptors (nicotinic receptors), and bethanechol, which 
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acts mainly on m-cholinoceptors (Goyal 1989), did not 
consistently increase duodenal bicarbonate output in man or 
animals (Ballesteros et al. 1991, Flemstrom et al. 1985, Lenz 
et al. 1989). Atropine, a non-specific antagonist at m1- and 
m2-cholinoceptors, inhibited basal but not sham-feeding 
stimulated bicarbonate secretion (Ballesteros et al. 1991, 
Fandriks 1986, Jonson et al. 1986, Lenz et al. 1989, Srnedfors 
et al. 1990). These disclosures insinuated that cholinergic 
stimulation of bicarbonate secretion did not utilize them-
cholinoceptor pathways. 
As an unexpected result, Safsten & Flemstrom (1986) 
reported that pirenzepine, an m1-cholinoceptor antagonist. 
(Goyal 1989), actually stimulated duodenal bicarbonate 
secretion in the rat in vivo. 
The n-cholinoceptor antagonist hexamethonium strongly 
curbed the effect of vagal stimulation of bicarbonate 
secretion, although this property was associated with 
systemic hypotension which itself depresses bicarbonate 
secretion (Fandriks 1986, Granstam et al. 1987, Nylander et 
al. 1987). The exact role of n-cholinoceptors, in any, was 
thus in doubt. 
Of note, there was good evidence that acetylcholine acts 
in the intestine by releasing the neuropeptide VIP (Cassuto 
et al. 1983) 
In summary, then, the extracellular cholinergic control 
of duodenal bicarbonate secretion was incompletely 
understood, and so required definitive characterization. As 
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a consequence, little was known about the intracellular 
second messenger, in particular ca2+, of this cholinergic 
mechanism. 
Approach to these issues: 
The following series of experiments were performed to 
address these issues pertaining to the cholinergic control 
of bicarbonate secretion. 
Dose-response data were obtained with carbachol to see 
whether this agent could be used to mimic cholinergic 
stimulation of bicarbonate secretion. 
The effects of atropine, pirenzepine and hexamethonium 
were studied on basal and carbachol-stimulated bicarbonate 
secretion to get further information on the nature of the 
cholinergic pathway of duodenal bicarbonate secretion. 
[D-p-Cl-Phe6 ,Leu1 7 )-vasoactive intestinal peptide, 
an antagonist to VIP, was tested in carbachol-stimulated 
bicarbonate secretion. 
Verapamil, nifedipine and the calcium ionophore A23187 
were employed to examine the role of intracellular ca2+ in 
cholinoceptor mediated stimulation of bicarbonate. Verapamil 
and nifedipine were tested for their effects on carbachol-
stimulated bicarbonate secretion. A23187 was tested dose-
responsively to determine whether it could be used as an 
agonist of bicarbonate secretion. Furthermore, the effect of 
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combining A23187 with carbachol or with the VIP-antagonist 
was assessed. 
An attempt was made in vitro to detect cholinoceptors 
on isolated duodenal enterocytes. 
5. REGULATORY ROLE OF SOMATOSTATIN IN DUODENAL BICARBONATE 
SECRETION 
The gas~rointestinal organs, particularly the stomach 
and duodenum, contain 70% of the body's somatostatin (Yamada 
& Chiba 1989, Lucey & Yamada 1989, Francis et al. 1990). 
Somatostatin exists as 14 and 28 amino acid peptides, 
derived by different processing of the common precursor 
prosomatostatin. The duodenum contains more somatostatin-14, 
located in the peptidergic neural system, than somatostatin-
28, found in the mucosa (Yamada & Chiba 1989). 
While somatostatin was shown to act in paracrine 
fashion to inhibit most gastrointestinal secretory processes 
(Yamada & Chiba 1989), its role in the regulation of 
duodenal bicarbonate secretion was not well understood. 
Somatostatin-14 had no effect on bicarbonate secretion 
by frog duodenum in vitro (Flemstrom et al. 1982b), and had 
variable effects on bicarbonate secretion by the perfused 
rat duodenum (Kirkegaard et al. 1984, Lenz & Forquignon 
1990). Somatostatin-14 decreased VIP-stimulated bicarbonate 
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secretion in the perfused rat duodenum (Kirkegaard et al. 
1984). Intravenous somatostatin-28 did not affect rat 
duodenal bicarbonate secretion (Lenz & Forquignon 1990). 
The role of somatostatin in duodenal bicarbonate 
secretion required further definition. It was decided to 
study in detail the 14 amino acid peptide form, which appears 
to act in the enteric neural system and which is likely to be 
that form which regulated bicarbonate secretion. 
Approach to these issues: 
Experiments was performed to gain more information on 
the regulation of bicarbonate secretion by somatostatin-14. 
The effects of somatostatin-14, carbachol, VIP and PGE2 
on bicarbonate secretion were tested in the perfused proximal 
duodenum of the guinea pig. 
Then, the effects of these agents on adenylate cyclase 
activity in homogenates of duodenal enterocytes were measured 
to determine the mechanism of action of somatostatin in the 
duodenum. 
6. FACILITATORY ROLE OF CARBONIC ANHYDRASE IN DUODENAL 
BICARBONATE SECRETION 
The intracellular transport mechanisms of duodenal 
bicarbonate secretion are incompletely characterized. The 
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role of carbonic anhydrase, however, is germane in this 
context, since this enzyme is postulated by most workers to 
constitute the final common step in the production of 
bicarbonate by the duodenal enterocytes (other sources of 
bicarbonate are also possible, such as diffused bicarbonate 
in the frog). 
This enzyme is present in most tissues and hydrates co2 
to produce Hco3- and H+ ions, a critical metabolic process 
in gastrointestinal acid/base transport (Gleeson 1992). 
Carbonic anhydrase is linked to ion exporters and exchangers 
at both the apical and basolateral cell membrane. 
Acetazolamide is a convenient metabolic tool which 
reversibly inhibits carbonic anhydrase activity by a process 
of N-sulfamyl substitution. Results of studies using this 
drug to inhibit bicarbonate secretion were however not 
consistent. 
In small mammals in vivo, the effect of acetazolamide 
was variable, and bicarbonate secretion was inhibited only 
when the basal rate of bicarbonate secretion was high, or 
when PGE 2 was used as an agonist (Flemstrom & Kivilaakso 
1983, Holm et al. 1990, Isenberg et al. 1983, Takeuchi et 
al. 1986). In the bullfrog duodenum in vitro, inhibition of 
carbonic anhydrase by acetazolamide (5 x 10-4 mol/L) did not 
affect basal bicarbonate secretion, whereas a quite large 
dose of acetazolamide (10-2 mol/L) produced 30% inhibition 
of basal bicarbonate secretion (Simson et al. 1981a). 
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In these reported studies using acetazolamide in 
animals, diffusion of bicarbonate from the blood to the 
lumen was not prevented since the duodenal lumen was 
perfused with isotonic NaCl which contained no bicarbonate, 
making possible passive diffusion of bicarbonate. 
Recently, it was reported that inhibition of carbonic 
anhydrase activity by acetazolamide did not alter 
bicarbonate secretion in the normal human stomach (Feldman & 
Goldschmiedt 1991), but reduced active bicarbonate transport 
in the human duodenum when the luminal perfusate contained 
24 mmol/1 NaHC03 (Knutson et al. 1992). 
Given the likelihood that carbonic anhydrase would 
serve as a final common pathway in bicarbonate secretion in 
the duodenum, it was elected to study in detail its actions 
in the basal and stimulated states of bicarbonate 
production. 
Approach to these issues: 
The final part of this thesis was planned to examine 
the effect of acetazolamide-inhibition of carbonic anhydrase 
on both basal and stimulated bicarbonate secretion as well 
as to locate the site of activity of carbonic anhydrase in 
the guinea pig duodenal crypt and villus structures. Again, 
emphasis was laid on the cholinergic, VIP and PGE2 pathways, 
but several other agonists were also examined in 
consideration of the concept of "final common pathway." 
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MATERIALS AND METHODS IN DETAIL 
1. GUINEA-PIG MODEL: PERFUSED DUODENAL LOOP WITH ACTIVE 
SECRETION OF BICARBONATE 
Surgical Procedures: 
Studies were performed in male albino guinea-pigs (250-
500 g, Weizman Institute, Rehovot, Israel). These were kept 
in a temperature (22°C) and light-controlled (12 hour day/12 
hour night) room and fed regular animal pelleted chow ad 
libitum. They were allowed to adjust to their new 
environment for at least 4 days prior to experimentation. 
They were deprived of food for 16-20 hours before the 
experiments, but were allowed free access to tap water up to 
the beginning of the experiments. 
Animals were anaesthetized with injection of urethane 
(1.5 g/kg, dissolved in 154 rnrnol/1 sterile NaCl) intra-
peritoneally, followed immediately by an injection of sodium 
indomethacin trihydrate (5 mg/kg, dissolved in 154 rnrnol/1 
sterile NaCl) intraperitoneally to inhibit endogenous 
prostaglandin synthesis (Flemstrom & Garner 1982). Body 
temperature was maintained at 37°c to 37.5°c by use of a 
heated blanket and lamp and controlled automatically by an 
intrarectal thermometer (Harvard Homeotherrnic Blanket 
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Control Unit, Harvard Inc., South Natick, MA, USA). A 
tracheostomy was performed and the animals breathed 
humidified room air spontaneously. 
One (occasionally two) external jugular vein was 
cannulated (polyethylene tubing I.D. 0.58 mm, Portex, Kent, 
England) for administration of a physiological solution (2 
ml/h, Harvard Apparatus Syringe Infusion Pump Model 22, 
Harvard Inc., South Natick, MA, USA) containing (in mmol/1) 
Na+ 145, K+ 2.5, ca2+ 0.75, Hco3- 24, c1- 124 and glucose 
5.5, and for injection of drugs as required. 
The abdominal cavity was opened by a midline incision, 
and the peritoneal cavity was rinsed with warm 154 mmol/1 
sterile NaCl to remove excess urethane. A 2 cm long loop of 
proximal duodenum was then fashioned between the bile and 
pancreatic ducts (which enter the duodenum separately in 
this species). A polyethylene catheter (I.D. 1.14 mm, 
Portex, Kent, England) was inserted into the duodenum just 
distal to the entry of the bile duct, and a ligature tied at 
this point; a second catheter exited the duodenum just 
proximal to the entry of the pancreatic duct, where another 
ligature was applied. Great care was taken not to disturb 
the vascular-neural supply of the duodenum or the free 
drainage of gastric and biliary secretions (via catheters 
inserted through the stomach wall) and pancreatic secretions 
(into the distal duodenum). 
The abdomen and neck were closed lightly and kept moist 
with warm 154 mmol/1 NaCl. 
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General Design of the Studies: 
The duodenal segment was perfused (0.5 ml/min, Harvard 
Apparatus Syringe Infusion Pump Model 22, Harvard Inc., 
South Natick, MA, USA) with a solution (37°c) containing 
NaHC03 24 mmol/1, with NaCl 130 mmol/1 added for isotonicity 
to 290 mOsmol/kg (Odes et al. 1990). Since the blood 
bicarbonate concentration in our anaesthetized guinea-pigs 
is verified by measurement to be 21 ± 1 mmol/1, this ensured 
that the duodenum was secreting bicarbonate into the lumen 
against a concentration gradient and not by diffusion. 
The duodenal perfusate solution was pre-gassed with 95% 
o 2 and 5% co2 to bring its pH down from 8.22 to 7.32, so 
that the infused solution entered the duodenum at a pH 
similar to plasma; gassing the solution with N2 , as in the 
back-titration method, rapidly returned its pH to the 
original value (Odes et al. 1990). 
After the resting bicarbonate output had become stable 
(usually by 20 min from the commencement of perfusion), the 
basal bicarbonate output was measured for a fixed period of 
40 min. 
Determination of Bicarbonate Output: 
The effluent from the duodenum was collected by 
continuous gravity drainage into glass measuring cylinders 
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in 10 min aliquots. The continuous drainage ensured that the 
duodenal segment never became distended, which might induce 
peristalsis, or that perfusate was retained. The 10 min 
volumes were carefully monitored to confirm that the 
recovered volumes exceeded the infused volumes (usually by 
0.2 to 0.5 ml/10 min). Volumes were read to the nearest 0.1 
ml and the bicarbonate content was measured immediately by 
back-titration (Odes et al. 1990). Duplicate, well-mixed 0.5 
ml samples of the effluent were acidified with 0.25 ml H2S04 
(100 rnmol/1), dissolved in 5 ml of CO2 free H20, gassed with 
N2 washed in Ba(OH)2, and titrated in glass cups, under 
continuous N2 gassing, with NaOH (15 rnmol/1) to end-point pH 
8.40 using automatic titration apparatus (pH Meter 82, 
Titrator 80, Autoburette 80, Titration Station 80, all from 
Radiometer, Copenhagen, Denmark). 
In each set of experiments, the concentration of NaOH 
was verified by titration to end-point pH 7.00 with 100 
mmol/1 HCl. The pH meter was calibrated daily with buffers 
of pH 7.00 and 10.00 (Radiometer, Copenhagen, Denmark). 
Standards of NaHC03 (24, 10 and 2.5 rnmol/1) were run daily. 
On randomly selected animals, pancreatic amylase was 
measured, by starch digestion method, to exclude the 
presence of aberrant pancreatic ducts in the segment. 
Amylase was not found. 
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Monitoring Procedures: 
Three procedures were used to monitor the health of the 
guinea-pig in these studies. 
The internal carotid artery was routinely cannulated and 
blood pressure and pulse were monitored continuously on a 
Gilson Polygraph (Gilson Medical Electronics, Middleton, WI). 
The integrity of the perfused duodenal loop was 
monitored using Multistix[R] (Ames, Stoke Poges, Slough, UK) 
to detect any blood, protein and glucose in the duodenal 
effluent. 
Also, duodenal segments were removed immediately at the 
conclusion of randomly selected experiments and placed in 
formalin for examination by light microscopy using 
haematoxylin and eosin staining. 
Any animals developing hypotension were not included; 
this was not common (2% of studies) and occurred where blood 
loss was excessive during the surgery, or where hexamethonium 
was infused i.v. Any evidence of damage to the duodenal loop 
meant that the experiment was discarded. Such events were not 
common. 
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Calculations: 
The amount of bicarbonate perfused through the duodenal 
lumen per 10 min period was subtracted from the recovered 
bicarbonate to yield the net secreted bicarbonate. The 
output of bicarbonate was expressed as µmol.cm-l.10 min-1 . 
Thirty min basal bicarbonate outputs were obtained by 
summing the three 10 min outputs obtained prior to the first 
injection of any test agent, and 30 min "stimulated" 
bicarbonate outputs by summing the first three 10 min-
periods following injection of a drug or combination of two 
drugs. In the series of experiments using the VIP-
antagonist, the 30 min bicarbonate outputs represented 
serial test periods. 
2. DETERMINATION OF ADENYLATE CYCLASE AND PROTEIN KINASE A 
IN ISOLATED DUODENAL ENTEROCYTES 
Male albino guinea-pigs were killed by a blow on the 
head and a 5 cm segment of the duodenum distal to the entry 
of the bile duct was resected immediately. 
Duodenal epithelial cells were isolated essentially 
according to the method of Weiser (1973). The lumen of the 
resected duodenum was flushed with ice-cold, oxygenated 
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saline. One end was clamped with a hemostat and the lumen 
filled with a buffer containing (in mmol/1) NaCl 96, KCl 1.5, 
Na-citrate 27, KzHP04 2.8, KHzP04 2.8, DTT 0.5; at pH 7.3. 
After 15 min of incubation at 370c with continuous o2 gassing 
the solution was discarded and the duodenum refilled with a 
solution containing (in mmol/L) NaCl 140, NazHP04 16, EDTA 
1.5, DTT 0.5; at pH 7.3. The duodenum was incubated twice for 
15 min at 37°C under continuous gassing in this buffer. The 
released cells were washed twice in HEPES-buffered saline 
containing (in mmol/1): NaCl 70, KCl 5, NaHzP04 0.5, Na2HP04 
1, NaHC03 20, HEPES 25, at pH 7.4, then resuspended in 
homogenization buffer (in mmol/L: TRIS-HCl 25, EDTA 0.1, DTT 
0.1; at pH 7.8) and sonicated (Branson Instruments; 30 W, 3 x 
5 sec). 
Adenylate cyclase activity in homogenates of the 
duodenal cells was determined by a competitive protein 
binding assay, based on Schwabe et al. (1974) as described 
by us (Reimer et al. 1992). Isolated cells (0.6 - 0.8 mg of 
protein per ml) were incubated in MEM supplemented with 1% 
bovine serum albumin (BSA, pH 7.4) at 37°C for the indicated 
periods of time under continuous gassing with 95% Oz/5% CO2. 
The incubation was terminated by heating aliquots of the 
cells to 95°C for 5 min. Subsequently, the denatured protein 
was pelleted at 10,000 g. Cyclic AMP content in the 
supernatant was determined by radioimmunoassay, as described 
previously by us. Standards were prepared in the incubation 
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medium and treated as the samples. Adenylate cyclase 
activity was expressed as pmol cAMP.mg protein-1 .min-1. 
Protein kinase assay: Isolated cells (1.5 - 2.0 mg of 
protein per ml) were incubated at 37°C for 30 min under the 
same conditions as described above, except that 0.1 mmol/1 
IBMX was included, as indicated. Incubations were stopped by 
cooling the cells on ice and washing them once in ice-cold, 
BSA-free incubation buffer containing 0.5 mmol/1 IBMX. The 
cells were disrupted by sonication in 1 ml homogenization 
buffer containing (mmol/1): TRIS/HCl 20 , sucrose 250, EDTA 
2, EGTA 1, NaCl 150, OTT 10; pH 7.4. For studying the 
subcellular distribution, the cell homogenate was 
centrifuged for 30 min at 100,000 x g. The supernatant 
recovered was used as the cytosolic fraction. The pellets 
were solubilized by stirring in 1 ml homogenization buffer 
containing 0.2% Triton-X 100 and used as a crude membrane 
preparation. Mg2+-dependent protein kinase activity was 
assayed by measuring the incorporation of 32po43- from ATP 
into histone in an assay mixture (0.2 ml) containing 
(mmol/1): Pipes/TRIS 10, EGTA 0.2, MgCl2 2, NaF 5, IBMX 0.1; 
pH 6.8 and 32P-ATP 40 µmol/1 (200-300 cpm/pmol), 50 µg 
histone (type II-A). To determine the total protein kinase A 
activity, 1 µmol/1 cAMP was included in the incubation 
medium, when indicated. The reaction was started by the 
addition of 20_)11 of enzyme preparation. Phosphorylation 
reaction was measured with 10 µg of enzyme preparation for 5 
min at 30°C. Under these conditions, the reaction rates were 
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linear with time. The reaction was stopped by the addition 
of 0.2 ml 10 % trichloroacetic acid (TCA) containing 
5 mmol/1 unlabelled ATP and 15 mmol/1 K2HP04 . The acid 
precipitable material was collected on Millipore membrane 
filters (pore size: 0.45 µm) and washed twice with 10 ml 5 % 
TCA. The incorporation of 32po43- into histone was measured 
by scintillation counting. 
3. DESIGN OF EXPERIMENTS IN THE GUINEA-PIG IN VIVO 
DUODENAL SEGMENT 
General note: To exclude any "placebo effects", the 
vehicles of all agents used were injected separately after 
the basal period of bicarbonate secretion; no effects on 
bicarbonate secretion were detected, and these data were 
omitted from the Results. 
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3.1. STIMULATORY ROLE OF PEPTIDE HORMONES, PROSTAGLANDINS 
AND CYCLIC NUCLEOTIDES ON BICARBONATE SECRETION 
Dose Response Studies: 
Basal bicarbonate output was measured for a period of 
40 min, as was done in all the experiments, and it was 
established that basal secretion was quite steady. It should 
be noted that the basal secretion rate does vary in 
relationship to animal weight, and this affects the peak 
response when agonists are administered. However, I prefer 
to show the exact values obtained in the experiments, rather 
than values which are "corrected for weight" that tend to 
distort the data. 
The structurally related peptides: VIP, glucagon and 
secretin were infused i.v. in increasing doses through the 
range 10-9, 10-8, 10-7 , 10-6 and 10-5 mol.kg-1 .30 min-1, and 
the bicarbonate output measured. This was done to enable a 
comparison of their potencies to be made. 
The effect of secretin on pancreatic bicarbonate 
secretion was also determined. Secretin was infused as 
described, and the pancreatic juice entering the duodenum 
was collected, diluted, and submitted immediately to back-
titration for measurement of bicarbonate secretion. 
In a separate experiment, TPA (lo-7 mol/kg) was infused 
over 30 min and the effect on bicarbonate secretion 
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measured; this agent was selected since it acts in cells 
directly via protein kinase c. 
The VIP-antagonist was infused (3.3 mg.kg-1, equal to 
10-6 mol/kg) together with VIP in another experiment to 
determine the specificity of the VIP-stimulation. 
In another study, the potency of VIP, dBcAMP, PGE2 and 
PGF2a was compared. Since VIP is thought to act via cAMP 
(Smith 1990), dBcAMP and PGE2 were tested, while PGF2a was 
selected for comparison because its mode of action is 
different. VIP, PGE2 and PGF2a were given i.v., while dBcAMP 
was administered by intraduodenal infusion (since we had 
determined that dBcAMP is more potent by this route compared 
with the i.v. route). All agents were infused in increasing 
doses (lo-9, 10-8, 10-7 and 10-6 mol.kg-l.30 min-1), each 
dose being given for 30 min. 
Then, dBcAMP, dBcGMP and theophylline were tested for 
their relative potency in stimulating active secretion of 
bicarbonate. All agents were infused i.v. in increasing 
doses (lo-9, 10-8,_ 10-7 and 10-6 mol.kg-l.30 min-1 ), with 
each dose being administered over 30 min. 
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Combinations of Agonists: 
The aforementioned experiments allowed a decision to be 
made as to which agonists were the most potent and suggested 
that both the adenylate cyclase/protein kinase A cascade and 
the inositol phospholipid/protein kinase C cascade 
participated in bicarbonate secretion. Experiments were then 
designed where two agonists were infused together to see 
whether additive effects on bicarbonate secretion would 
occur. 
The combined infusion of glucagon with VIP will 
illustrate the design of these experiments. Glucagon (10-6 
mol.kg-1.30 min-1 ) was infused, after the basal period, for 
90 min, and VIP (lo-11 mol.kg-l.30 min-1) was infused in the 
middle 30 min period of the glucagon infusion. Therefore, 
glucagon was infused alone before and after the combined 
glucagon and VIP infusion. The effect of glucagon was to 
stimulate bicarbonate secretion. The question was, whether 
VIP would further increase the bicarbonate secretion. It 
will be noted that glucagon was given in a dose that cannot 
produce maximal bicarbonate secretion; in other words, the 
glucagon dose was submaximal. The VIP dose was relatively 
low, but able to stimulate bicarbonate secretion. 
Similarly experiments were performed on the following 
combinations: 
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glucagon (lo-6 mol.kg-1.30 min-1) and PGE2 (lo-7 mol.kg-l.30 
min-1}; 
glucagon (10-6 mol.kg-1 .30 min-1 } and PGF2a (10-6 mol.kg-
1.30 min-1); 
VIP (lo-ll mol.kg-1.30 min-1} and PGE2 (10-7 mol.kg-1.30 
min-1 }; 
VIP (lo-11 mol.kg-1.30 min-1) and PGF2a (10-6 mol.kg-1.30 
min-1 ); 
PGE2 (10- 7 mol.kg-1 .30 min-1) and PGF2a (10-6 mol.kg-1.30 
min-1 ); 
dBcAMP (5 x 10-8 mol.kg-1} and PGE2 (5 x 10-7 mol.kg-1}; 
dBcAMP (5 x 10-8 mol.kg-1) and VIP (5 x 10-9 mol.kg-1). 
In all cases the doses used were submaximal and the 
objective was to see whether the effects on duodenal 
bicarbonate secretion were additive. 
Detection of Intracellular Messengers: 
These related studies were performed at the Medical 
School, Hannover, Germany (Dr Reimer). The effect of PGE2 
and VIP on the generation of cAMP and protein kinase 
activity in homogenates of isolated duodenal enterocytes was 
measured. 
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3.2. CHOLINERGIC STIMULATION OF BICARBONATE SECRETION 
Effects on Basal Bicarbonate Secretion of Selected 
Cholinergic Agonists and Antagonists: 
After basal bicarbonate secretion was measured, 
injections of the following agonists were administered: 
(1) carbachol (in the doses 0.2 µg.kg- 1.s min-1, which 
equals 10-9 mol.kg-1.s min-1 ; and 2 µg.kg-1.s min-1 , which 
equals 10-8 mol.kg-1.s min-1); 
(2) calcium ionophore A23187 (5, 50 and 500 µg.kg-1.5 min-
1, corresponding to 10-8 , 10-7 and 10-6 mol.kg-1 .5 min-1 ). 
These agents were infused i.v. in a volume of 0.5 ml 
over 5 minutes to determine their effects on basal 
bicarbonate secretion. The increasing doses of carbachol and 
A23187, as specified, were used to obtain dose-response data 
for these drugs; these doses were administered in random 
order at 40 min intervals. 
The following agents were tested for their inhibitory 
effect on basal bicarbonate output. 
(1) atropine (0.1 mg.kg-1.s min-1, corresponding to 1.5 x 
10-7 mol.kg-1 .5 min-1); 
(2) pirenzepine (1 mg.kg-1.s min-1 , corresponding to 2 x 
10-6 mol.kg-1 .5 min-1); 
(3) hexamethonium (0.3 mg.kg-1.5 min-1, corresponding to 
10-6 mol.kg-1 .5 min-1 ); 
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(4) verapamil (0.2 mg.kg- 1 .s min-1, which corresponds to 4 
x 10-7 mol.kg-1.s min-1). 
These agents were also infused i.v. in a volume of 0.5 
ml over 5 minutes to determine their effects on basal 
bicarbonate secretion. 
By the end of 30 min after any of these treatments, the 
bicarbonate output had returned to basal. 
Effect of Inhibition of Carbachol-Stimulated Bicarbonate 
Secretion: 
In this series of experiments, the effect on carbachol-
stimulated bicarbonate secretion was tested of the 
anticholinergics: atropine, pirenzepine and hexamethonium, 
and the ca2+ channel blockers verapamil and nifedipine. 
After basal bicarbonate secretion was determined, carbachol 
(2 µg.kg-1.s min-1, corresponding to 10-8 mol.kg-1.s min-1) 
was injected i.v. on three occasions every 40 min; atropine 
(0.1 mg.kg-1.s min-1), pirenzepine (l mg.kg-1.s min-1), 
hexamethonium (0.3 mg.kg-1.s min-1), verapamil (0.2 mg.kg-
1.s min-1) or nifedipine (1.7 mg.kg-1.s min-1, corresponding 
to 5 x 10-6 mol.kg-1.s min-1) was injected i.v. 5 minutes 
prior to the second administration of carbachol. 
Role of VIP in the Cholinergic Stimulation of Duodenal 
Bicarbonate Secretion: 
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The role of VIP in the cholinergic pathway of duodenal 
bicarbonate secretion was examined using VIP and the VIP-
antagonist [D-p-Cl-Phe6 ,Leu1 7 ]-VIP. 
The effect of the antagonist on basal and VIP-
stimulated bicarbonate secretion was examined. After basal 
bicarbonate output was measured for 30 min, sequential 30-
min i.v. infusions were administered of the antagonist alone 
(3.3 mg.kg-1), then the antagonist (3.3 mg.kg-1 , or 10-6 
mol/kg) and VIP (5 µg.kg- 1 ) simultaneously via different 
veins, and finally VIP (5 µg.kg- 1 ) alone. 
Next, after determination of basal bicarbonate output, 
the VIP-antagonist (3.3 mg.kg-1) and carbachol (4 µg.kg-1) 
were infused i.v. simultaneously for 30 min, followed by 
carbachol (4 µg.kg-1) alone for another 30 min. 
Thirdly, the effect of pirenzepine (1 mg.kg-1.5 min-1) 
or atropine (0.1 mg.kg-1.5 min-1) on VIP-stimulated 
bicarbonate secretion was tested by infusing VIP 5 µg.kg- 1 
for 3 periods of 30 minutes, while pirenzepine or atropine 
was injected prior to the second VIP treatment. 
The VIP-antagonist was given as a continuous infusion 
since it has a very short half-life (Algazi et al. 1989). 
For this reason, VIP, carbachol and A23187 were also infused 
continuously in these experiments. 
In addition, the role of VIP in A23187-stimulation of 
bicarbonate secretion was also determined, as follows. After 
stimulation by A23187 was determined, the effect of [D-p-Cl-
Phe6,Leu17]-VIP on A23187-stimulated bicarbonate secretion 
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was tested by infusing the VIP-antagonist during stimulation 
with A23187. 
Detection of M-Cholinoceptors on Duodenal Enterocytes; 
Measurement of Intracellular ca2+ after Cholinergic 
Stimulation: 
The intention was to find out if duodenal enterocytes 
have muscarinic cholinergic receptors. Basolateral membranes 
prepared from isolated duodenal enterocytes were tested for 
their ability to bind 3H-N-methylscopolamine. Intracellular 
ca2+ levels were determined in isolated intact duodenal 
enterocytes in the basal state and after stimulation with 
carbachol and related secretagogues. These experiments were 
performed on our behalf by Dr. R Reimer and the details of 
the methodology were recently published (Reimer et al. 
1993a). 
3.3. ROLE OF SOMATOSTATIN IN DUODENAL BICARBONATE SECRETION 
Somatostatin and Basal Bicarbonate Secretion: 
In the first series of experiments, basal bicarbonate 
secretion was determined for 30 minutes, and then 
somatostatin-14 was infused intravenously in the dose of 
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10-ll mol/kg over 30 minutes; this was followed by further 
sequential infusions of somatostatin-14 in the doses of 10-9 
mol/kg and 10-7 mol/kg, each for 30 minutes, to determine 
the effect of this peptide on basal bicarbonate secretion. 
Then, PGE 2 10-6 mol/kg was infused for the final 30 minutes 
to demonstrate the bicarbonate secretory capacity of the 
duodenum. 
Somatostatin and Stimulated Bicarbonate Secretion: 
In the next series of experiments, after basal 
bicarbonate secretion had been determined, carbachol (lo-8 
mol/kg), VIP (lo-8 mol/kg) and PGE2 (10-8 mol/kg) were 
infused i.v. for three consecutive periods of 30 minutes 
each; somatostatin-14 (lo-7 mol/kg) was infused during the 
second 30 minute period of agonist-infusion. 
Effect of Somatostatin on CAMP Formation: 
Adenylate cyclase activity in homogenized duodenal 
enterocytes was measured in the basal state as well as in 
the presence of somatostatin (lo-6 mol/1), carbachol (lo-3 
mol/1), VIP (lo-8 mol/1) or PGE2 (lo-7 mol/1). The effect of 
somatostatin in the presence of these agonists was also 
tested. 
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3.4. ROLE OF CARBONIC ANHYDRASE ENZYME IN DUODENAL 
BICARBONATE SECRETION 
Dose-Response Effect of Acetazolamide on Basal Bicarbonate 
Secretion: 
The role of carbonic anhydrase in bicarbonate secretion 
was studied using acetazolamide. After measuring the 
bicarbonate output under basal conditions for 30 minutes, 
acetazolamide was infused i.v. as a single dose of 80 
mg.kg-1.5 min-1 (which is equal to 3.6 x 10-4 mol/kg), and 
the effect on bicarbonate secretion was noted. 
Effect of Inhibition of Carbonic Anhydrase on Stimulated 
Bicarbonate Secretion: 
The role of carbonic anhydrase in stimulated 
bicarbonate secretion was also studied. The following 
agonists, that utilize different intracellular messengers, 
were infused i.v. for three consecutive periods of 30 
minutes each: PGE2 (lo-6 mol.kg-1 .30 min-1 ), PGF2a (10-6 
mol.kg-l.30 min-1), TPA (10- 7 mol.kg-1 .30 min-1), glucagon 
(lo-7 mol.kg-l.30 min-1), VIP (lo-8 mol.kg-1 .30 min-1 ) and 
carbachol (lo-8 mol.kg-1.30 
min-1). Similarly, dBcAMP (10-5 mol.kg-1 .30 min-1 ) and 
dBcGMP (10-5 mol.kg-l.30 rnin-1 ) were infused 
intraduodenally. Acetazolarnide, in the dose of 80 mg.kg-1 .5 
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min-1, was infused by a separate vein during the middle 30 
minute period of agonist-stimulation for each of these 
agents. 
Histochemical Localization of Carbonic Anhydrase in the 
Duodenum of the Guinea-Pig: 
A duodenal segment corresponding to the perfusion 
studies in vivo was removed and quickly rinsed in isotonic 
saline. Pieces of 1 cm were immediately frozen in liquid 
nitrogen. From these specimens, 10 µm sections were prepared 
in a cryostat at -25°C and mounted on glass slides. For the 
demonstration of carbonic anhydrase according to Dermietzel 
et al. (1985), the sections were incubated with 100 µl of 
5.10-5 mol/1 dimethylamino-naphthaline-5-sulfonamide (DNSA) 
in phosphate buffered saline for 10 min at room temperature. 
For counterstaining of nuclei, the sections were incubated 
additionally with propidium iodide (5 µg/ml) for 10 sec. 
Control sections of duodenum were incubated with DNSA in the 
presence of the nonfluorescent inhibitor acetazolamide (1 
mmol/1). Sections of guinea pig stomach, known to be rich in 
carbonic anhydrase, were incubated with DNSA for a positive 
control. The blue fluorescence of the carbonic anhydrase-DNSA 
complex was visualized and photographed using a fluorescence 
microscope (Olympus, Germany) at an excitation wavelength of 
470 nm. 
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4. SOURCES OF REAGENTS 
All drugs and chemicals were purchased from Sigma, St 
Louis, MO, except indomethacin which was a gift from Merck 
Sharp & Dohme, Rahway, NJ, USA, and the synthetic 
prostaglandins E2 and F2a which were kind gifts from the 
Upjohn Co., Kalamazoo, MI, USA. 
All drugs were freshly prepared on the days of 
experiment. Most drugs were dissolved in 154 rnrnol/1 NaCl. 
VIP was dissolved in 154 rnrnol/1 NaCl which also 
contained 1 rnrnol/1 ascorbic acid. The VIP-antagonist [D-p-Cl-
Phe6,Leu17J-VIP which was dissolved in 154 rnrnol/1 NaCl with 
0.1% bovine serum albumin and 1 rnrnol/1 ascorbic acid added. 
Glucagon was dissolved in 154 rnrnol/1 NaCl containing 0.5 
mg/ml bovine serum albumin and 15 mmol/1 NaOH at pH 8.9, and 
the pH was then adjusted to 7.4 with 100 mmol/1 HCl. The 
prostaglandins were dissolved in a few drops of absolute 
ethyl alcohol and diluted in 100 rnrnol/1 phosphate buffer. The 
ca2+ ionophore A23187 was dissolved in dimethyl sulfoxide 
(DMSO). 
50 
5. STATISTICAL ANALYSIS 
Results are shown as mean± SEM for at least 4 animals 
or preparations, unless indicated otherwise. Each animal 
served as its own control. Student's paired t-test (and 
sometimes unpaired test) and analysis of variance were used 
to compute the statistical significance of differences, and 
P values< 0.05 were considered to be significant. Where 
multiple P values of varying degrees of significance were 
obtained, and it was felt that printing each specific P 
value would be burdensome to the reader and not add to the 
meaning of the observations, the general term "Pat least> 
0.05" was employed. 
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RESULTS 
VALIDATION OF THIS MODEL: ACTIVE SECRETION OF BICARBONATE IN 
VIVO 
To test, whether bicarbonate is actively secreted by 
the guinea-pig duodenum, the lumen was perfused with 24 
mmol/1 NaHco3 , made isotonic to the body fluid with NaCl. 
The results show that bicarbonate secretion in the presence 
of luminal 24 mmol/1 NaHco3 was equal to the secretion 
obtained during perfusion with 154 mmol/1 NaCl alone (Fig. 
1) • 
MONITORING PROCEDURES 
The luminally perfused duodenal loops retained their 
normal colour and configuration during the studies. 
Histological examination (Fig. 2) of the duodenum showed 
that the tissues remained healthy and revealed no signs of 
degeneration at the end of the experiments. Brunner's glands 
were occasionally evident in the submucosa. Blood, protein 
and glucose were absent from the duodenal effluent. The 
blood pressure (130/90 mm Hg) and pulse rate were stable and 
within the normal range with all the drugs tested in the 
doses indicated, except hexamethonium, which induced severe 
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hypotension (systolic pressure 50 mm Hg) and bradycardia 
immediately when injected, with slow recovery to normal over 
60 min. 
It should be noted that higher doses of some of the 
tested agents adversely affected the blood pressure, 
preventing us from measuring a saturation kinetic for these 
agonists. 
STIMULATION OF DUODENAL BICARBONATE SECRETION BY PEPTIDE 
HORMONES, PROSTAGLANDINS AND CYCLIC NUCLEOTIDES 
Dose-Response Interrelationships of Agonists of Bicarbonate 
Secretion: 
Basal bicarbonate secretion varied in the range of 8 to 
29 µmol.cm-1.30 min-1, depending on animal weight. 
VIP increased duodenal bicarbonate secretion 
significantly in a dose-response manner (Fig. 3). The effect 
of the VIP-antagonist [D-p-Cl-Phe6,Leu17]-VIP on basal and 
VIP-stimulated bicarbonate secretion was studied. Duodenal 
bicarbonate secretion was 10.5 + 0.5 µmol.cm-1.30 min-1 
under basal conditions, 10.6 ± 1.1 µmol.cm-l.30 min-1 during 
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FIGURE 1. Basal bicarbonate secretion in the isolated guinea-pig proximal duodenum perfused with 154 mmol/1 NaCl 
or 24 mmol/1 NaHC03 (plus 130 mmol/1 NaCl for isotonicity). 
The bicarbonate secretion in the presence of luminal NaHco3 was equal to the secretion obtained during perfusion with NaCl alone. n = 6. 
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FIGURE 2. Histology of isolated guinea-pig duodenal segment 
at the conclusion of a typical experiment. The tissue is well 
preserved and no signs of degeneration are evident. Very 
small numbers of Brunner's glands are seen in the submucosa; 
their contribution to bicarbonate secretion is regarded as 
slight (see Text). 
55 
-cu 
en 
as 
.a 
-0 
'iP-
-C 
0 
i 
... 
~ 
en 
G) 
-as C 
0 
.a 
... 
as 
0 
m 
FIGURE 3. Concentration response relationship of selected 
peptide hormones for stimulation of duodenal bicarbonate 
secretion. Basal bicarbonate secretion was the following: 
VIP 8.6 ± 1.1 µmol.cm-l.30 min-1, glucagon 9.9 ± 0.7 
µmol.cm-l.30 min-1 and secretin 9.5 ± 0.6 µmol.cm-l.30 min-
1. All agents were infused i.v. Values are mean± SEM from 4 
to 8 animals.Pat least< 0.05 for differences from basal 
and between all doses for VIP and for glucagon. Secretin did 
not stimulate duodenal bicarbonate secretion. 
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infusion of [D-p-Cl-Phe6 ,Leu17 ]-VIP (10-6 mol.kg-1 , or 3.3 
mg.kg-1) alone, and 12.7 ± 1.0 µmol.cm- 1 .30 min- 1 (P = NS) 
when the VIP-antagonist and VIP (5 µg.kg- 1 ) were infused 
simultaneously. VIP alone stimulated the bicarbonate 
secretion to 21.1 ± 1.5 µmol.cm- 1 .30 min- 1 (P < 0.01). The 
effect of VIP was therefore completely inhibited by the VIP-
antagonist [D-p-Cl-Phe6 ,Leu17 ]-VIP in the dose 3.3 mg.kg-1 . 
Glucagon increased duodenal bicarbonate secretion in a 
dose-dependant fashion (Fig. 3). VIP was more potent than 
glucagon on a molar basis (P < 0.005). Secretin, given at 
even higher doses than glucagon, had no effect on the 
duodenal bicarbonate secretion (Fig. 3); in this dose range, 
secretin however increased pancreatic bicarbonate output 
from 282 to 1473 µmol.30 min-1. 
In another experiment, VIP (given i.v.), PGE2 (given 
i.v.) and dBcAMP (given intraduodenally) were shown to 
stimulate bicarbonate secretion significantly up to 400% of 
the basal output in a dose-dependent manner (Fig. 4). 
Intraduodenal application of dBcAMP was 30% more effective 
in stimulation of bicarbonate secretion than i.v. 
application of this agonist. Furthermore, dBcAMP was 
arithmetically more potent than VIP, which was somewhat more 
potent than PGE 2 , but these differences were not 
statistically significant (Table 2). 
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TABLE 2. Rank order of potency of the agonists of duodenal 
bicarbonate secretion. 
Agonist (10-8 mol/kg) HC03- Secretion(% of basal) 
dBcAMP * 338 ± 14 a 
VIP 297 ± 10 b 
PGE2 273 ± 37 C 
Carbachol 260 ± 15 a,d 
Theophylline 219 ± 25 a,b,c,e 
dBcGMP 181 ± 14 a,b,c,d 
PGF2a 169 ± 14 a,b,c,d 
Glucagon 154 ± 11 a,b,c,d,e 
Basal bicarbonate secretion was 100%. Each agonist was 
infused i.v. for 30 minutes. There was no statistically 
significant difference between dBcAMP, VIP and PGE2. Agonists 
with shared superscripts showed significant differences (Pat 
least< 0.05; n at least 4). In addition, TPA (10-7 mol/kg) 
increased basal bicarbonate secretion by 274 ± 14% (P < 
0.05). 
* Note that dBcAMP was given intraduodenally and the other 
agents i.v.; the comparison with dBcAMP may therefore Il.Q.t be 
valid. 
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FIGURE 4. Concentration response relationship of selected 
agonists for stimulation of duodenal bicarbonate secretion. 
Basal bicarbonate secretion in these experiments was as 
follows: VIP 12.0 ± 0.9 µmol.cm-l.30 min-1, PGE2 17.1 ± 2.0 
µmol.cm-l.30 min-1, PGF2a 16.0 ± 0.6 µmol.cm-l.30 min-1 and 
dBcAMP 13.2 ± 0.5 µmol.cm- 1 .Jo min-1 • VIP, PGE2 and PGF2a 
were infused i.v. and dBcAMP was given intraduodenally. 
Values are mean± SEM from 4 to 6 animals.Pat least< 0.05 
for differences from basal and between doses for all the 
agonists tested. 
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Infusion of PGF2a also increased duodenal bicarbonate 
secretion, although this effect was very small compared to 
all the other agonists (Fig. 4). PGF2a, at the dose of 10-6 
mol/kg, increased bicarbonate secretion to 80% above the 
basal value. PGF2a was much less potent than PGE2 (P < 0.005, 
Table 2). 
The agonists dBcAMP, theophylline and dBcGMP all 
increased duodenal bicarbonate secretion (Fig. 5). The most 
potent agonist was dBcAMP; dBcGMP was about one-third as 
potent as dBcAMP at equivalent molar doses (P < 0.001). 
Carbachol increased duodenal bicarbonate secretion as 
follows: when basal bicarbonate secretion was 100%, carbachol 
10-9 mol/kg stimulated the secretion to 211 ± 15% and 
carbachol 10-8 mol/kg stimulated the secretion to 260 ± 14% 
(n = 5, P < at least 0.05). (These data are considered more 
fully below and in Fig. 8). 
Comparing the molar potency of all the agonists tested 
in t.his section, there were arithmetic but not statistical 
differences between dBcAMP, VIP and PGE2 (Table 2). Carbachol 
was less potent than dBcAMP (P < 0.005), but did not differ 
from VIP or PGE2. Theophylline was less potent than dBcAMP, 
VIP and PGE2 (P < 0.05). dBcGMP, PGF2a and glucagon were all 
of lower potency. As noted above, secretin was not an agonist 
of duodenal bicarbonate secretion. 
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Relationship between Intracellular cAMP, Protein Kinase A and 
Bicarbonate Production: 
Data produced in the in vivo experiments in the guinea-
pig were combined with the in vitro data obtained from 
isolated guinea-pig duodenal enterocytes (performed by Dr. 
Reimer, in order to establish the temporal relationship 
between intracellular cAMP levels, PKA activity and 
bicarbonate secretion. 
Fig. 6 shows the temporal relationship between 
intracellular cAMP levels, PKA activity and bicarbonate 
secretion in the guinea-pig treated with VIP. 
Isolated duodenal cells were incubated in the presence 
of 10-7 mol/1 VIP in the absence of the phosphodiesterase 
inhibitor IBMX. Intracellular cAMP levels were maximal at 5 
min of incubation. PKA activity, given as the ratio of 
activity assayed in the absence and presence of 1 µmol/1 
cAMP, reached a maximum after 15 min of incubation. Duodenal 
bicarbonate secretion, stimulated by i.v. infusion of VIP in 
the dose 10-10 mol/kg, was maximal at 30 min. These data fit 
together nicely to show that VIP stimulation leads to the 
generation of c.AMP in the duodenal enterocytes, followed by 
activati_pn of pr-otein kinase A, and finally by secretion of 
bicarbonate into the duodenal lumen. Exactly the same 
61 
FIGURE 5. Concentration response relationship of dBcAMP, 
dBcGMP and theophylline for stimulation of duodenal 
bicarbonate secretion. Basal bicarbonate secretion was as 
follows: dBcAMP 13.2 ± 0.5 µmol.cm-1.30 min-1, dBcGMP 8.2 ± 
0.4 µmol.cm-l.30 min-1 and theophylline 7.9 ± 0.2 µmol. cm-
l.30 min-1. The agonists were injected i.v. Values are mean 
± SEM from 6 animals.Pat least< 0.05 for differences from 
basal and between doses for all agonists tested. 
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FIGURE 6. Time-course of effects after VIP treatment in the 
guinea-pig proximal duodenum. In one experiment, isolated 
duodenal enterocytes were incubated in the presence of VIP 
(lo-7 mol/1); at the indicated time points, an aliquot of 
cells was removed and intracellular cAMP and protein kinase A 
activity were determined. In a separate experiment, VIP (10-
10 mol.kg-l.30 min-1) was administered i.v. to anaesthetized 
guinea-pigs and bicarbonate secretion from the perfused 
duodenal segment was measured. Values shown are 
representative of at least three different cell preparations 
or animals, which all gave similar results. All values are 
plotted on the same x-axis for comparison of time-related 
events. 
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relationship was found after stimulation in vitro and in 
vivo with PGE2 in similar dosages. (Reimer et al. in press). 
Combinations of Agonists: Evidence that Multiple 
Intracellular Messengers modulate Bicarbonate Secretion: 
The data obtained above suggested that both the 
adenylate cyclase/protein kinase A cascade (activated by 
dBcAMP, VIP, PGE 2 , theophylline) and the inositol 
phospholipid/protein kinase C cascade (activated by PGF2a, 
TPA, dBcGMP) participated in bicarbonate secretion. 
Experiments were then designed where two agonists were 
infused together to see whether additive effects on 
bicarbonate secretion would occur. The results appear in 
detail in Tables 3 to 9, and in Fig. 7. 
The interaction of glucagon and VIP illustrates the 
type of experiment. After basal bicarbonate secretion was 
stable (8.1 ± 0.9 µmol.cm-1 .10 min-1 (note: 10 min!), 
glucagon was infused in the dose 10-6 mol.kg-1 for 30 min. 
This was associated with a significant increase in the 
bicarbonate secretion above the basal (P < 0.001). Then, 
while the glucagon infusion continued, VIP 10-ll mol.kg-1 
was infused simultaneously, and this produced a significant 
drop of bicarbonate secretion, which returned to basal 
values (P < 0.005 versus glucagon alone). When VIP was 
discontinued and glucagon was infused on its own again, the 
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bicarbonate secretion rate returned to its former stimulated 
value (Fig. 7, Table 3). Therefore, VIP served to inhibit 
bicarbonate secretion, and this was not associated with 
changes in the blood pressure of the animals (local duodenal 
blood flow was not measured). 
Similarly, PGE 2 (Table 4) reduced the stimulatory 
effect of glucagon on bicarbonate secretion. 
However, PGF2a increased the glucagon-stimulated 
bicarbonate output when these agents were infused together 
(Table 5). The bicarbonate outputs were as follows: basal 10 
± 1 µmol.cm- 1 .30 min-1 , glucagon alone 14 ± 1 µmol.cm- 1 .30 
min-1 (P < 0.005 versus basal}, glucagon plus PGF2a 18.2 ± 2 
(P < 0.005 versus glucagon). 
When VIP and PGE2 were infused together, the 
bicarbonate output fell below the basal value (P < 0.001, 
Table 6). However, the combination of VIP with PGF2a 
increased bicarbonate secretion above the stimulated value 
of VIP on its own (P < 0.005, Table 7). 
The effect of infusing PGE 2 and PGF2a together is shown 
in Table 8. PGE 2 stimulated the bicarbonate output above the 
basal value (P < 0.005). The bicarbonate secretion during 
infusion of both PGE 2 and PGF2a was greater than during 
treatment with PGE2 alone (P < 0.025). 
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FIGURE 7. Effect of VIP on glucagon-stimulated duodenal 
bicarbonate secretion. After basal bicarbonate secretion was 
measured for 30 min, glucagon (lo-6 mol.kg-1) was infused 
i.v. for 90 min. VIP (lo-11 mol.kg-1) was infused i.v. 
simultaneously during the time period indicated. Values are 
mean± SEM from 5 animals. *Pat least< 0.05 for differences from basal. 
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TABLE 3. Effect of combined i.v. infusion of glucagon and 
VIP on duodenal bicarbonate secretion 
basal 
glucagon 
glucagon + VIP 
glucagon 
HC03- Secretion 
µmol.crn-1.30 rnin-1 
26 ± 1 
41 ± 1* 
27 ± 2** 
41 ± 1* 
% of basal 
100 
156 ± 5* 
105 ± 5** 
159 ± 3* 
Doses of the agonists: glucagon: 10-6 rnol.kg-l.30 rnin-1; VIP: 
10-ll mol.kg-l.30 min-1. Glucagon was infused for 3 periods 
of 30 min each, in sequence; VIP was infused simultaneously 
during the second period of glucagon-infusion. Values are 
mean± SEM, n = 5. 
* P < 0.001 greater than basal 
** P < 0.005 versus glucagon alone 
N..o.:t..e: While it is usual to depict the interactions between 
pharmacologic agents on isobolograms, the data were tabulated 
instead (Tables 3 to 9) since full dose relationships of 
these agents were not determined. 
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TABLE 4. Effect of combined i.v. infusion of glucagon and 
PGE 2 on duodenal bicarbonate secretion 
basal 
glucagon 
glucagon + PGE 2 
glucagon 
Hco3- Secretion 
µmol.cm-1.30 min-1 
24 ± 2 
43 ± 3* 
29 ± 4** 
46 ± 3* 
% of basal 
100 
183 ± 17* 
126 ± 19** 
194 ± 10* 
Doses of the agonists: glucagon: 10-6 mol.kg-1.30 min-1; 
PGE2 : 10-7 mol.kg-1.30 min-1. Glucagon was infused for 3 
periods of 30 min each, in sequence; PGE2 was infused 
simultaneously during the second period of glucagon-
infusion. Values are mean± SEM, n = 5. 
* P < 0.01 greater than basal 
** P NS versus basal, P < 0.005 less than glucagon alone 
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TABLE 5. Effect of combined i.v. infusion of glucagon and 
PGF20 on duodenal bicarbonate secretion 
basal 
glucagon 
glucagon + PGF20 
glucagon 
Hco3- Secretion 
10 ± 1 
14 ± 1* 
18 ± 2** 
13 ± 1* 
% of basal 
100 
142 ± 7* 
185 ± 12** 
135 ± 7* 
Doses of the agonists: glucagon: 10-6 mol.kg-l.30 min-1; 
PGF 20 : 10-6 mol.kg-l.30 min-1. Glucagon was infused for 3 
periods of 30 min each, in sequence; PGF20 was infused 
simultaneously during the second period of glucagon-
infusion. Values are mean± SEM, n = 6. 
* P < 0.005 greater than basal 
** P < 0.005 greater than glucagon alone 
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TABLE 6. Effect of combined i.v. infusion of VIP and PGE2 
on duodenal bicarbonate secretion 
basal 
VIP 
VIP+ PGE2 
VIP 
Hco3- Secretion 
µmol.cm- 1 .30 min-1 
29 ± 2 
41 ± 2* 
12 ± 2** 
36 ± 2* 
% of basal 
100 
140 ± 6* 
39 ± 4** 
124 ± 4* 
Doses of the agonists were: VIP: 10-11 mol.kg-l.30 min-1; 
PGE 2 : 10-7 mol.kg-1.30 min-1. VIP was infused for 3 periods 
of 30 min each, in sequence; PGE2 was infused simultaneously 
during the second period of VIP-infusion. Values are mean± 
SEM, n = 6. 
* P < 0.005 greater than basal 
** P < 0.001 versus basal, P < 0.001 versus VIP alone 
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TABLE 7. Effect of combined i.v. infusion of VIP and PGF2a 
on duodenal bicarbonate secretion 
Hco 3- Secretion 
µmol.cm-l.30 min-1 % of basal 
basal 
VIP 
VIP + PGF2a 
VIP 
27 ± 1 
39 ± 1* 
47 ± 1** 
40 ± 1* 
100 
142 ± 4* 
171 ± 4** 
147 ± 3* 
Doses of the agonists: VIP: 10-11 mol.kg-1 .30 min- 1 ; PGF2a: 
10-6 mol.kg-1.30 min-1. VIP was infused for 3 periods of 30 
min each, in sequence; PGF2a was infused simultaneously 
during the second period of VIP-infusion. Values are mean± 
SEM, n = 7. 
* P < 0.001 greater than basal 
** P < 0.005 greater than VIP alone 
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TABLE 8. Effect of combined i.v. infusion of PGE2 and PGF2a 
on duodenal bicarbonate secretion 
basal 
PGE2 
Hco3- Secretion 
27 ± 1 
38 ± 2* 
48 ± 3** 
38 ± 2* 
% of basal 
100 
146 ± 8* 
184 ± 11** 
145 ± 6* 
Doses of the agonists: PGE2 : 10-7 mol.kg-l.30 min-1; PGF2a: 
10-6 mol.kg-l.30 min-1. PGE2 was infused for 3 periods of 30 
min each, in sequence; PGF2a was infused simultaneously 
during the second period of PGE2-infusion. Values are mean± 
SEM, n = 6. 
* P < 0.005 greater than basal 
** P < 0.025 greater than PGE2 alone 
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TABLE 9. Effect of dBcAMP, PGE 2 and VIP, given alone and in 
combination, on duodenal bicarbonate secretion 
Duodenal Hco3- secretion(% of basal) 
Basal 100 
PGE2 277 ± 21 * 
VIP 229 ± 15 * 
dBcAMP 366 ± 16 * 
dBcAMP + PGE2 252 ± 1 ** 
dBcAMP + VIP 304 ± 18 *** 
dBcAM.P (5 x 10-8 mol.kg-1), PGE2 (5 x 10-7 mol.kg-1) and VIP 
(5 x 10-9 mol.kg-1) were injected i.v. in separate veins 
over 5 min, alone or in the combinations indicated. Duodenal 
bicarbonate secretion was collected over a 30 min period. 
Values are mean± SEM, n = 4. 
* 
** 
*** 
significantly higher than basal (P < 0.005) 
significantly lower than dBcAMP alone (P < 0.005) 
P = NS versus dBcAMP alone 
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PGE 2 and VIP were shown to reduce the stimulatory 
effect of dBcAMP on bicarbonate secretion (P < 0.005), 
although the 
level of secretion was still greater than the basal output 
(Table 9). 
These data therefore indicate that the combination, in 
submaximal doses, of two agonists, which both utilize the 
adenylate cyclase and protein kinase A cascade, leads to 
reduced bicarbonate output than when one agonist of the pair 
is administered alone (examples: glucagon and VIP, glucagon 
and PGE2, VIP and PGE2, dBcAMP and PGE2, dBcAMP and VIP). 
Certainly, there was no additive effect, as we had 
anticipated. 
However, there was a surnrnative effect when an agonist 
acting in the adenylate cyclase/protein kinase A cascade was 
combined with an agonist acting the inositol phospholipid 
and protein kinase C cascade (example: VIP and PGE2a, PGE2 
and PGF2a, glucagon and PGF2a)• To this must be added the 
observation that carbachol also stimulated bicarbonate 
secretion. 
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CHOLINERGIC PATHWAYS OF BICARBONATE SECRETION 
Effect of Cholinergic Stimulation of Basal Bicarbonate 
Secretion: 
Basal bicarbonate output was steady at 13.7 + 0.5 
µmol.cm-1 .30_min-1. 
Following the i.v. injection of 0.2 µg.kg-1.5 min-1 
(lo-9 mol.kg-1.s min-1) carbachol, the bicarbonate output 
rose abruptly to 28.8 ± 1.6 µmol.cm- 1 .30 min- 1 (P < 0.001 
versus basal) and then returned to basal by 30 min (Fig. 8). 
Carbachol 2 µg.kg- 1 .5 min-1 (lo-8 mol.kg-1.5 min-1 ) 
produced a significantly greater increase in bicarbonate 
secretion to 35.6 ± 1.7 µmol.cm-1.30 min-1 (P < 0.001 versus 
basal, and versus the lower carbachol dose). 
Although the order of the two carbachol doses was 
randomized, the stimulatory effect of each dose was 
reproducible (unpaired t test showed no statistical 
difference between the bicarbonate outputs in 3 animals 
receiving the lower and then the higher carbachol dose, and 
2 animals receiving the carbachol doses in reverse order). 
75 
Effect of Muscarinic Blockade of Basal Bicarbonate 
Secretion: 
The effect of muscarinic inhibition by atropine and 
pirenzepine on basal duodenal bicarbonate secretion was 
studied first. 
Atropine 0.1 mg.kg- 1 .5 min-1 (equal to 1.5 x 10-7 
mol.kg-1 .5 min- 1 ) i.v. reduced the bicarbonate secretion 
from basal 10.2 ± 1.2 µmol.cm-l.30 min-1 to 4.1 + 2.7 
µmol.cm- 1 .30 min- 1 (P < 0.05). 
Pirenzepine 1 mg.kg-1 .5 min-1 (equalling 2 x 10-6 
mol.kg-1.5 min-1) i.v. similarly diminished the duodenal 
bicarbonate secretion from basal 12.3 ± 1.3 µmol.cm-1.30 
min-1 to -3.3 ± 1.3 µmol.cm- 1 .30 min- 1 (P < 0.01). The 
"negative" value -3.3 ± 1.3 µmol.cm- 1 .30 min- 1 indicates 
absorption of bicarbonate from the hyperconcentrated 
perfusate in the duodenal lumen. 
Effect of Muscarinic Blockade of Stimulated Bicarbonate 
Secretion: 
The effect of m-cholinoceptor blockade on carbachol-
stimulated duodenal bicarbonate secretion was studied next. 
Three doses of carbachol (2 µg.kg-1.5 min-1, equal to 
10-8 mol.kg-1.5 min-1) were infused i.v. consecutively at 40 
min intervals. Atropine (0.1 mg.kg-1.5 min-1) or pirenzepine 
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FIGURE 8. Effect of carbachol i.v. infusion on duodenal 
bicarbonate secretion in the anaesthetized guinea-pig. 
Carbachol was infused in two doses, 0.2 µg.kg-1.s min-1 and 
2.0 µg.kg-1.s min-1 (corresponding to 10-9 mol.kg-1.s min-1 
and 10-8 mol.kg-1.s min-1), at 40 min intervals. The 
isolated duodenal loop was perfused with a solution 
containing 24 mmol/1 Hco3- (and 130 mmol/1 NaCl for 
isotonicity). Values are mean+ SEM for n = 5 animals. * P 
at least< 0.05 versus basal. 
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TABLE 10. Effect of atropine, pirenzepine and hexamethonium 
on carbachol-stimulated bicarbonate output 
Basal Carbachol Carbachol 
+ Antagonist 
------------------------------------------------------------
Bicarbonate (µmol.cm-1.30 min- 1 ) 
Atropine 11 + 0.1 35 + 1.5 a 7 + 1. 0 b,c 
-
(0.1 mg) 
Pirenzepine 11 + 0.5 33 + 3.2 b 9 + 0.7 d,e 
( 1 mg) 
Hexamethonium 8 ± 0.3 23 ± 1.0 a 6 ± 0.3 d,e 
(0.3 mg) 
All drugs (doses/kg) were infused i.v. over 5 min. 
Bicarbonate secretion stimulated by carbachol given alone at 
the conclusion of each experiment was not significantly 
different from that produced by the first infusion of 
carbachol alone (data not shown). Values are mean± SEM from 
at least 4 animals. 
a P < 0.001 vs basal 
b p < 0.005 vs basal 
C p < 0.001 vs carbachol 
d p < 0.025 vs basal 
e P < 0.005 vs carbachol 
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(1 mg.kg-1.s min-1) was injected 5 min prior to the second 
carbachol dose. Both drugs abolished the stimulatory effect 
of carbachol and reduced the bicarbonate output to values 
below basal (Fig. 9, Table 10). 
In the doses used, the effects of atropine and 
pirenzepine on carbachol-stimulated duodenal bicarbonate 
secretion were similar. Furthermore, the effect of each drug 
was short-lived. 
Effect of Nicotinic Blockade on Bicarbonate Secretion 
Hexamethonium in the dose 0.3 mg.kg-1.s min-1 (10-6 
mol.kg-1.s min-1) given by i.v. infusion significantly 
inhibited the stimulatory effect of 2 µg.kg-1.s min-1 
carbachol on duodenal bicarbonate secretion (P < 0.001) 
(Fig. 9 and Table 10). 
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FIGURE 9. Effects of atropine (0.1 mg.kg-1.s min-1, 
corresponding to 1.5 x 10-7 mol.kg-1.s min-1), pirenzepine 
(l.O mg.kg-1.s min-1, corresponding to 2 x 10-6 mol.kg-1.s 
min-1) or hexamethonium (0.3 mg.kg-1.s min-1, corresponding 
to 10-6 mol.kg-1.s min-1) on carbachol-stimulated duodenal 
bicarbonate secretion in anaesthetized guinea-pigs. 
Carbachol (2 µg.kg-1.s min-1, corresponding to 10-8 mol.kg-
1.s min-1) was infused i.v. at 40 min intervals on three 
occasions. The antagonists were infused i.v. 5 min before 
the second dose of carbachol. The isolated duodenal loop was 
perfused with a solution containing 24 mmol/1 Hco3- (and 130 
mmol/1 NaCl for isotonicity). Values are mean± SEM for n = 
6 animals (atropine and pirenzepine) and n = 4 animals (hexamethonium). *Pat least< 0.05 compared with basal. 
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In these experiments there was a sharp drop of blood 
pressure (from mean 110 to mean 50 mm Hg) upon injection of 
hexamethonium, followed by slow recovery over the succeeding 
60 min. Therefore, the reduction of bicarbonate output to 
below basal occurred during the period of hypotension 
(systolic blood pressure of 50 mm Hg). 
Rapid intravenous infusion of physiological solution 
failed to prevent or correct this hypotension. 
Role of VIP in the Cholinergic Stimulation of Bicarbonate 
Secretion: 
The effect of the VIP-antagonist [D-p-Cl-Phe6,Leu17J-VIP 
on carbachol-stimulated bicarbonate secretion was studied. 
Duodenal bicarbonate secretion was 9.4 ± 0.8 
µmol.cm-l.30 min-1 in the basal state and 8.0 ± 0.9 µmol. 
cm-1.30 min-1 (P < 0.025) during infusion of the VIP-
antagonist [D-p-Cl-Phe6,Leu17J-VIP (10-6 mol.kg-1, or 3.3 
mg.kg-1). Simultaneous infusion of VIP-antagonist and 
carbachol (2 µg.kg-1) reduced the bicarbonate secretion to 
5.0 ± 0.4 µmol.cm-1.30 min-1 (P < 0.005 versus basal; the 
reason for this is not known). Discontinuation of the 
infusion of VIP-antagonist resulted in a 3-fold increase in 
bicarbonate secretion in response to carbachol alone, 14.3 ± 
0.6 µmol.cm-1.30 min-1 (P < 0.025). 
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Effect of Muscarinic Blockade on VIP-Stimulated Bicarbonate 
Secretion: 
In a further experiment, the basal bicarbonate was 
measured as 8.6 ± 0.1 µmol.cm-1.30 min-1. VIP (5 µg.kg-1) 
was infused for 3 periods of 30 minutes, and pirenzepine 
(1 mg.kg-1.5 min-1) was injected prior to the second VIP 
treatment. Bicarbonate secretion was: 16.2 ± 0.9, 16.6 ± 1.0 
and 15.9 ± 0.6 µmol.cm- 1 .30 min-1 respectively (P = NS, 
Table 11). 
In another experiment, atropine (0.1 mg.kg-1.5 min-1) 
was injected in place of pirenzepine during VIP-stimulated 
bicarbonate secretion. Bicarbonate outputs were as follows: 
basal 7.6 ± 0.4 µmol.cm-l.30 min-1, atropine and VIP 
infusion 12.0 ± 0.8 µmol.cm- 1 .30 min- 1 (P = NS versus basal, 
n = 3), VIP (alone) infusion 18.5 ± 0.9 µmol.cm-1.30 min-1 
(P < 0.025 versus basal secretion, Table 11). 
Subtracting the basal bicarbonate secretion from 
atropine plus VIP-induced secretion yielded a value of 4.4 ± 
1.2 µmol.cm-l.30 min-1. Subtracting the basal bicarbonate 
from VIP-induced secretion yielded 10.9 ± 1.2 µmol.cm- 1 .30 
min-1 (P < 0.01 versus the atropine plus VIP). This implies 
that atropine (0.1 mg.kg-1.5 min-1 ) reduced VIP-stimulated 
bicarbonate secretion by about 60%. 
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TABLE 11. Effect of muscarinic blockade by pirenzepine and 
atropine on VIP-stimulated duodenal bicarbonate secretion 
Pirenzepine Atropine 
Bicarbonate secretion (µmol.cm- 1 . 30 min- 1 ) 
Basal 8.6 ± 0.1 7.6 ± 0.4 
VIP 16.2 ± 0.9 a ND 
VIP + antagonist 16.6 ± 1.0 a 12.0 ± 0.8 b 
VIP 15.9 ± 0.6 a 18.5 ± 0.9 C 
Doses were: pirenzepine 1 mg.kg-1, atropine 0.1 mg.kg-1, VIP 
5 µg.kg- 1 • 
a p < 0.05 versus basal 
b p = NS versus basal 
c p < 0.025 versus basal 
Effect of Muscarinic Blockade on PGE2-stimulated Bicarbonate 
Secretion: 
Pirenzepine (1 mg.kg-1.5 min-1) had no effect on PGE2 
(10-7 mol/kg)-stimulated bicarbonate secretion. In this 
study, basal bicarbonate secretion was 8.6 ± 0.4 µmol.cm-
l.30 min-1. PGE2 increased the bicarbonate secretion sharply 
to 31.1 ± 2.1 µmol.cm-1.30 min- 1 (P < 0.001). During PGE2 
plus pirenzepine infusion, the bicarbonate production was 
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31.2 ± 0.6 µmol.cm- 1 .30 min-1 • In the final period when PGE 2 
was infused alone, the bicarbonate production was 28.8 ± 0.4 
µmol.cm-l.30 min-1 (P = NS for these values). 
Similarly, atropine (0.1 mg.kg-1.s min-1) had no effect 
on PGE2-stimulated bicarbonate secretion (data not shown, 
but similar to pirenzepine data). 
The effect of hexamethonium on PGE2-stimulated 
bicarbonate secretion was not tested, since the hypotensive 
effects of this drug make the results questionable. 
ROLE OF INTRACELLULAR ca2+ IN THE CHOLINERGIC STIMULATION OF 
BICARBONATE SECRETION 
Effects of verapamil and ca2+ Ionophore A23187 on Basal 
Bicarbonate Secretion: 
The calcium-channel blocking agent verapamil and the 
ca2+ ionophore A23187 were infused i.v. to study their 
effect on basal duodenal bicarbonate secretion. 
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FIGURE 10. Effect of A23187 on duodenal bicarbonate 
secretion in anaesthetized guinea-pigs. The ionophore (5, 
50, 500 µg.kg-1.5 min-1, corresponding to 10-8, 10-7 and 10-
6 mol.kg-1.s min-1) was infused i.v. over 5 min every 40 
min. DMSO (the vehicle of A23187) had no effect. The 
isolated duodenal loop was perfused with a solution 
containing 24 mmol/1 ttco3- (and 130 mmol/1 NaCl for 
isotonicity). Values are mean± SEM for n = 6 animals. 
* P < 0.05 compared with basal. 
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FIGURE 11. Effect of verapamil (0.2 mg.kg-1.s min-1, 
corresponding to 4 x 10-7 mol.kg-1.s min-1) or nifedipine 
(1.7 mg.kg-1.s min-1, corresponding to 5 x 10-6 mol.kg-1.s 
min-1) on carbachol-stimulated duodenal bicarbonate 
secretion in anaesthetized guinea-pigs. Carbachol (2 µg.kg-
1.s min- 1 , corresponding to 10-8 mol.kg-1.s min-1) was 
infused i.v. at 40 min intervals on three occasions. 
Verapamil or nifedipine was infused i.v. 5 min before the 
second injection of carbachol. The isolated duodenal loop 
was perfused with a solution containing 24 mmol/1 Hco3- (and 130 mmol/1 NaCl for isotonicity). Values are mean± SEM for 
n = 6 animals. *Pat least< _0.05 compared with basal. 
Carbachol Carbachol 
· 1 6 ?* Carbachol ?* ? - 14 \ \t ..... • Vera pa mil C 12 V Nifedipine Nifedipine or ·-E Verapamil V 10 .+J 0 
*? 0 - * C * 0 )( 8 V .0 I V L. 
-
'* 
I 0 I I 0 \ 
·- E 6 V I CD 0 I y I )( 
4 I 
'y 0 
.A' V E //v ::t 2 y / 
'--' 
0 >I-~ 
-2 
0 20 40 60 BO 100 120 140 160 
Time (min) 
86 
180 
Verapamil (0.2 mg.kg-1.5 min-1 ) decreased the duodenal 
bicarbonate secretion from a basal value of 10.8 ± 0.4 
µmol.cm-l.30 min-1 to 3.1 ± 1.5 µmol.cm- 1 .30 min-1 
(P < 0.01). 
Calcium ionophore A23187 in the dose range 5 to 500 
µg.kg-1.5 min-1 increased bicarbonate secretion 
significantly (Fig. 10). The 30 min bicarbonate outputs 
after A23187 in the doses 5, 50 and 500 µg.kg-1.5 min-1 
were: 11.2 ± 1.4 µmol. 
cm-1.30 min-1, 15.2 ± 1.1 µmol.cm- 1 .30 min-1 and 17.2 ± 0.5 
µmol.cm- 1 .30 min-1 respectively, compared with basal 7.4 + 
0.6 µmol.cm-1.30 min-1 (P < 0.025 for all changes). The 
vehicle (DMSO) of A23187 did not affect duodenal bicarbonate 
secretion (7.8 ± 0.7 µmol.cm-l.30 min-1). 
Effects of Verapamil, Nifedipine and the Calcium Ionophore 
A23187 on Carbachol-Stimulated Bicarbonate Secretion: 
The effect of modulating intracellular ca2+ on 
carbachol-stimulated duodenal bicarbonate secretion was 
studied by infusing three doses of carbachol (2 µg/kg over 5 
min) at 40 min intervals; verapamil (0.2 mg.kg-1.5 min-1), 
nifedipine (1.7 mg.kg-1 .5 min-1) or A23187 (0.5 mg.kg-1.s 
min-1 ) was injected i.v. just prior to the second carbachol 
dose. Verapamil and nifedipine both abolished completely the 
stimulatory effect of carbachol, and the duodenal 
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bicarbonate secretion was reduced to below basal with each 
drug (Fig. 11, Table 12). 
By comparison, A23187 increased the bicarbonate 
secretion above that obtained with carbachol alone (Table 
12). The basal bicarbonate secretion was 14.0 ± 0.5 µmol. 
cm-1.30 min-1, carbachol alone produced a bicarbonate output 
of 41.4 ± 1.0 µmol.cm-l.30 min- 1 (P < 0.05 versus basal), 
carbachol plus A23187 produced a bicarbonate output of 46.6 
± 1.4 µmol.cm-1 .30 min-1 (P < 0.05 versus carbachol alone), 
and carbachol alone at the end of the experiment produced a 
bicarbonate output of 40.3 ± 1.5 µmol.cm-l.30 min-1 (P < 
0.05 versus basal). 
The modest degree of the increase in carbachol-
stimulated bicarbonate secretion induced by adding A23187 is 
due to the near maximum rate of bicarbonate secretion 
already achieved by carbachol alone. 
Effect of VIP-antagonist on A23187-stimulated bicarbonate 
secretion: 
The effect of [D-p-Cl-Phe6,Leu1 7 ]-VIP (3.3 mg.kg- 1 .30 
min-1) on A23187 (500 µg.kg-l.30 min-1)-stimulated 
bicarbonate secretion was studied. 
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TABLE 12. Effect of verapamil, nifedipine and A23187 on 
carbachol-stimulated bicarbonate output 
Basal Carbachol Carbachol 
+ agonist 
or antagonist 
Bicarbonate (µmol.cm-1.30 min-1) 
verapamil 
(0.2 mg) 
12 ± 1. 3 
Nifedipine 12 ± 0.3 
( 1. 7 mg) 
A23187 
(0.5 mg) 
10 ± 0.7 
37 ± 3.3 a 5 ± 1.5 b,c 
22 ± 0.8 a 5 ± 0.6 C 
27 ± 4.8 b 31 ± 5.2 d,e 
All drugs (doses/kg) were infused i.v. over 5 min. 
Bicarbonate secretion stimulated by carbachol infused given 
alone at the conclusion of each experiment (see methods) was 
not significantly different from that produced by the first 
infusion of carbachol alone (data not shown). Values are 
mean± SEM from at least 4 animals. 
a P < 0.001 vs basal b P < 0.01 vs basal 
c P < 0.001 vs carbachol d P < 0.005 vs basal 
e p < 0.025 vs carbachol 
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The bicarbonate output was 11.2 ± 0.6 µmol.cm-l.30 min-1 
under basal conditions, 10.8 ± 0.8 µmol.cm-l.30 min-1 during 
treatment with [D-p-Cl-Phe6,Leu17]-VIP, and 10.7 ± 0.6 
µmol.cm-1.30 min-1 during simultaneous treatment with [D-p-
Cl-Phe6, Leu17]-VIP plus A23187 (P = NS for these changes). 
The bicarbonate output rose to 20.8 ± 0.7 µmol.cm-l.30 min-1 
during infusion of A23187 alone at the end of this experiment 
(P < 0.001). 
M-Cholinoceptors and Intracellular ca2+ in the Duodenal 
Enterocytes: 
There was a virtual absence of 3H-N-methylscopolamine 
binding and no rise of the intracellular ca2+ concentration 
in response to carbachol stimulation of isolated duodenal 
enterocytes, as reported separately by Reimer et al. (1993a) 
who performed these measurements on our behalf. 
This indicates that the duodenal enterocytes contain 
very few m-cholinoceptors and that carbachol stimulation of 
duodenal bicarbonate secretion requires an intermediary 
messenger. We have shown that this is the neuropeptide, VIP, 
which acted via cAMP and protein kinase A. 
It should be noted, that protein kinase C also 
participates in bicarbonate secretion, as shown by the brisk 
response to stimulation of the duodenum in vivo with TPA. 
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EFFECT OF SOMATOSTATIN ON BICARBONATE SECRETION 
Effect of Somatostatin on Basal Bicarbonate Secretion: 
Basal bicarbonate output was 10.5 ± 0.5 µmol.cm-1.30 
. -1 nun • 
During the first intravenous infusion of somatostatin 
(lo-11 mol.kg-1.30 min-1), the bicarbonate output decreased 
. 1 t 3 4 + 6 1 1 -l 30 . -1 th t' progressive y o - . - . µmo .cm . nun , e nega ive 
value indicating absorption of bicarbonate from the lumen (P 
< 0.05 vs. basal, Fig. 12). The subsequent infusions of 
larger doses of somatostatin (10-9, 10-7 mole/kg) produced 
significantly greater negative values (P < 0.05 vs. 
preceding concentrations). 
PGE 2 , infused at the end of the experiment, stimulated 
the bicarbonate secretion to 17.2 ± 1.3 mol.kg-1.30 min-1 (P 
< 0.01 vs. basal). 
Effect of Somatostatin on Carbachol-Stimulated Bicarbonate 
Secretion: 
Carbachol (10-8 mol.kg-l.30 min- 1 ) increased the 
bicarbonate secretion from basal 9.0 ± 0.5 to 23.3 ± 2.7 
µmol.cm-1.30 min-1 (P < 0.025, Fig. 13). 
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During infusion of somatostatin (lo-7 mol/kg), the 
bicarbonate output was 3.0 ± 2.2 µmol.cm-1.30 min-1 (P < 
0.001 versus carbachol alone). When carbachol was again 
infused on its own, the secretion of bicarbonate rose to its 
previous stimulated level (21.4 ± 2.8 µmol.cm-1.30 min-1). 
Effect of Somatostatin on VIP-Stimulated Bicarbonate 
Secretion: 
VIP (lo-8 mol.kg-l.30 min-1) increased the bicarbonate 
secretion from basal 9.5 ± 0.5 to 19.9 ± 1.4 µmol.cm-l.30 
min-1 (P < 0.005, Fig. 13). During somatostatin infusion 
(lo-7 mol/kg), the bicarbonate output was 6.4 ± 3.9 µmol.cm-
1.30 min-1 (P < 0.05 versus VIP alone). 
In the subsequent period when VIP alone was infused, 
the bicarbonate secretion was 20.6 ± 2.7 µmol.cm-1.30 min-1. 
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FIGURE 12. Effect of somatostatin-14 (lo-11 mol.kg-1, 10-9 
mol.kg-1 and 10-7 mol.kg-1) on basal duodenal bicarbonate 
secretion. Each dose was infused i.v. for 30 min. At the end 
of the study, PGE2 (10-6 mol.kg-1) was infused i.v. to test 
the secretory capacity of the duodenum. The isolated 
duodenal loop was perfused with a solution containing 24 
mmol/1 HCo3- (and 130 mmol/1 NaCl for isotonicity). Values 
are mean± SEM for n = 8 animals. * P < 0.05 compared with 
basal. 
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FIGURE 13. Effect of somatostatin-14 (lo-7 rnol.kg-1) on 
duodenal bicarbonate secretion stimulated by carbachol (lo-8 
mol.kg-1) and VIP (10-8 mol.kg-1). Carbachol or VIP was infused i.v. in three consecutive periods of 30 min, and 
somatostatin was infused during the second 30 min period. The isolated duodenal loop was perfused with a solution 
containing 24 rnmol/1 HCo3- (and 130 rnmol/1 NaCl for isotonicity). Values are mean± SEM for n = 4 animals. * P < 0.05 compared with basal. 
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Effect of Somatostatin on PGE2-stimulated Bicarbonate 
Secretion: 
PGE 2 (10-8 mol.kg-l.30 min-1) increased the bicarbonate 
secretion from basal of 8.9 ± 0.2 µmol.cm-1.30 min- 1 to 21.5 
± 1.1 µmol.cm-l.30 min- 1 (P < 0.001, Fig. 14). 
The bicarbonate output during the period of combined 
infusion with somatostatin (lo-7 mol/kg) was 23.0 ± 2.0 
1 -1 30 . -1 µmo .cm • min • 
Subsequently, when PGE2 was again infused on its own, 
the bicarbonate output was 22.7 ± 1.2 µmol.cm-1.30 min- 1 (P 
= NS). 
Somatostatin had no effect on PGE 2-stimulated duodenal 
bicarbonate secretion. 
Effect of Somatostatin on Duodenal Enterocytic Adenylate 
Cyclase Activity: 
Adenylate cyclase activi~y in homogenates of duodenal 
enterocytes (Table 13) was 9.4 ± 1.0 pmol cAMP.mg-1.min-l in 
the basal state, and 9.1 ± 1.7 pmol cAMP.mg-1.min-l in the 
presence of somatostatin (10-6 mol/1). 
VIP (10-8 mol/1) and PGE 2 (lo-7 mol/1) stimulated basal 
adenylate cyclase activity to 21.8 ± 3.6 and 30.9 ± 5.3 
pmol.mg-l.min-1, respectively. There was no detectable 
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effect of somatostatin on PGE2-stimulated and VIP-stimulated 
adenylate cyclase activity (Table 13). 
carbachol in a high dose (10- 3 mol/1) had no affect on 
basal adenylate cyclase activity, therefore the combination 
of carbachol with somatostatin was not tested. 
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FIGURE 14. Effect of somatostatin-14 (lo-7 mol.kg-1) on 
duodenal bicarbonate secretion stimulated by PGE2 (lo-8 
mol.kg-1). PGE2 was infused i.v. in three consecutive 
periods of 30 min, and somatostatin was infused during the 
second 30 min period. The isolated duodenal loop was 
perfused with a solution containing 24 nunol/1 Hco3- (and 130 
nunol/1 NaCl for isotonicity). Values are mean± SEM for n = 
4 animals. Somatostatin did not affect PGE2-stimulated HC03-
secretion. 
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TABLE 13. Adenylate cyclase activity (measured as pmol 
cAMP.mg-1.min-1) in homogenized duodenal enterocytes treated 
with somatostatin and three agonists of duodenal Hco3-
secretion 
Basal 
Carbachol 
VIP 
PGE2 
Agonist 
alone 
9.4 ± 1.0 
9.9 ± 0.3 
21.8 ± 3.6* 
30.9 ± 3.9* 
Agonist + 
somatostatin 
9.1 ± 1.7 
ND 
20.7 ± 2.0* 
28.0 ± 3.9* 
Doses in mo1.1-l: somatostatin 10-6, carbachol 10-3, VIP 
10-8, PGE2 10-7. Vaues are expressed as mean± SEM (n = 4). 
ND, not done. *Pat least< 0.05 compared with basal. 
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EFFECT OF INHIBITION OF CARBONIC ANHYDRASE BY ACETAZOLAMIDE 
Effect of Acetazolamide on Basal Bicarbonate Secretion: 
Basal bicarbonate output was shown to be 3.4 ± 0.2 
µmol.cm- 1 .10 min-1 (Fig. 15). 
Following the intravenous infusion of acetazolamide 
(3.6 x 10-4 mol.kg-1 .s min-1, or 80 mg.kg-1.s min-1 ), the 
bicarbonate output decreased abruptly over a 20 minute 
period. The "negative values" of bicarbonate obtained 
indicated absorption of luminally perfused 24 mmol/1 Hco3-
along a concentration gradient (as stated, the blood of the 
anaesthetized guinea-pig was verified to contain 21 ± 1 
mmol/1 ttco3-). 
Subsequently, there was a steady increase of 
bicarbonate secretion and a return to the steady basal level 
within 1 hour. 
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FIGURE 15. Effect of acetazolamide (80 mg.kg-1.s min-1 
i.v.) on basal bicarbonate secretion by the isolated guinea-pig duodenum that was perfused with an isotonic solution 
containing 24 mol/1 NaHco3 . Net bicarbonate secretion is 
plotted in the upper portion of the graph and blood pressure 
in the lower portion. Values are mean± SEM for n = 5 
animals. SEM for blood pressure was< 5 nun Hg. *: p < 0.05 
vs. basal. 
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Effect of Acetazolamide on VIP-Stimulated Bicarbonate 
Secretion: 
VIP (lo-8 mol.kg-1 .30 min-1) i.v. significantly 
increased duodenal bicarbonate secretion from basal 3.4 ± 
0.3 to maximum 10.8 ± 1.4 µmol.cm-l.10 min-1 (Fig. 16). 
During the combined infusion with acetazolamide (dose 
3.6 x 10-4 mol.kg-1.s min-1, or 80 mg.kg-1.s min-1), the 
bicarbonate output was significantly reduced to 2.1 ± 1.9 
µmol.cm- 1 .10 min-1. 
In the post-acetazolamide period, when VIP was infused 
on its own again, the bicarbonate output rapidly returned to 
its former stimulated secretion rate of 9.8 ± 0.9 µmol. 
cm-l.10 min-1. 
Effect of Acetazolamide on PGE 2-stimulated Bicarbonate 
Secretion: 
Acetazolamide (3.6 x 10-4 mol.kg-1.s min-1) similarly 
reduced the bicarbonate output after stimulation with PGE 2 
(10-6 mol.kg-1 .30 min-1 , Fig. 16). 
101 
Effect of Acetazolamide on Blood pH: 
Blood gas and pH analysis was performed, to verify that 
there was no systemic acidosis, in at least one animal in 
each series of studies (i.e., effect of acetazolamide on 
basal bicarbonate secretion, and effect of acetazolamide on 
agonist stimulated bicarbonate secretion). There was no 
detectable acidosis in these animals. There were no changes 
of blood pressure in all the animals tested with 
acetazolamide. 
Effect of Acetazolamide on Bicarbonate Secretion stimulated 
by Multiple Agonists: 
Acetazolamide (3.6 x 10-4 mol.kg-1.s min-1) also reduced 
the bicarbonate output in response to stimulation with the 
agonists and secretory stimulants: VIP, prostaglandins, 
glucagon, carbachol, TPA and dBcAMP and dBcGMP (Table 14). 
These were all the agonists examined in this work. 
These agonists alone stimulated bicarbonate secretion up 
to 275% of basal output. During the period of combined 
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FIGURE 16. Effect of acetazolamide (80 mg.kg-1.s min-1 i.v.) on VIP-and PGE 2 stimulated bicarbonate secretion by 
the guinea pig duodenum. The agonists VIP (10-8 mol.kg-1.Jo 
min-1) or PGE2 (10-6 mol.kg- 1 .Jo min-1 ) were given i.v. for 
three consecutive periods of 30 minutes. The isolated duodenal loop was perfused with a solution containing 24 
mmol/1 Hco3- (and 130 mmol/1 NaCl for isotonicity). Net bicarbonate secretion is plotted in the upper portion of the graph and blood pressure in the lower portion. values are mean± SEM, n = 4 animals. *: p < 0,05 vs. basal. 
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pc; r.2 
VIP 
Table 11,.Effect of acetazolamide infusion on stimulated bicarbonate secretion by the 
guinea-pig proximal duodenum. The agonists were infused iv (VIP, PGE2, PGF2a, 
glucagon, carbachol, TPA) or intraduodenally (dBcAMP, dBcGMP) for three consecutive 
periods of 30 minutes, and acetazolamide (80 mg/kg iv for 5 min) was infused at the 
beginning of the second 30 minute period. Values are mean ± S.E.M. for n = 4 animals. 
Agonist 
(mol/kg) 
VIP (10-8) 
PGE2 (10-6) 
PGF2cx (10-6) 
Glucagon (10-7) 
Carbachol (1 o-8) 
TPA (10-7) 
dBcAMP (1 o-5) 
Basal 
9.1 ± 0.5 
8.5 ± 0.4 
10.4 ± 1.4 
9.9±0.5 
9.6 ± 0.7 
8.2 ± 0.4 
6.9 ± 0.7 
Agonist alone 
25.1 ± 1.23 
17.0 ± 1.23 
17.1 ± 2.33 
16.3 ± o.aa 
20.2 ± 2.03 
22.5 ± 2.03 
15.3 ± 2.oa 
dBcGMP (10-5) 9.4 ± 0.7 12.9 ± 1.6a 
a: p < 0.05 vs. basal; b: p < 0.05 vs. agonist alone. 
Agonist + 
acetazolamide 
7.0 ± 3.4b 
1.0 ± 2.5ab 
4.6 ± 1.3ab 
2.7 ± o.aab 
0.5 ± 3.9b 
-0.1 ± 3.oab 
1.4 ± 3.1b 
1.3 ± 1.oab 
Agonist alone 
25.0 ± 1.23 
17.7 ± 2.03 
17.6 ± 1.83 
20.1 ± 1.6a 
20.5 ± 2.03 
24.3 ± o.aa 
14.4 ± 2.83 
13.1 ± 1.63 
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infusion of the respective agonists with acetazolamide, the 
bicarbonate output was significantly reduced, to Oto 72 % 
of basal secretion. 
During subsequent infusion of each agonist alone, 
bicarbonate secretion returned to its former stimulated 
secretion rate. 
Cellular Localization of Carbonic Anhydrase: 
Carbonic anhydrase could be detected in all epithelial 
cells from the duodenal crypts up to the villi, except in 
the goblet cells (Fig. 17). The staining was present in the 
whole cytoplasm; no specific subcellular localization could 
be detected. The DNSA-fluorescence in Brunner's glands in 
the submucosa was faint (Fig. 17). 
The specificity of this technique was demonstrated by 
the complete absence of fluorescence when incubating the 
sections with DNSA in the presence of 1 mmol/1 
acetazolamide. Of note, the DNSA-fluorescence of the stained 
duodenal specimens was lower than in sections from guinea 
pig stomach (the control, results not shown). 
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FIGURE 17. Carbonic anhydrase fluorescence in cryo-sections of the guinea-pig proximal duodenum. The section is slightly oblique, showing villi (V) and crypts (C). The whole 
epithelium from the crypts to the top of the villi shows a white fluorescence, which indicates the presence of the 
carbonic anhydrase-dimethylamino-naphthaline-5-sulfonamide complex in the mucosa! cells. Brunner's glands (B) in the 
submucosa are scanty in this species and stain very faintly fo~ carbonic anhydrase/DNSA complex. 
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DISCUSSION 
ACTIVE SECRETION OF BICARBONATE: THE GUINEA-PIG MODEL 
The first objective of this research was to set up a 
model where active bicarbonate secretion could be measured, 
that is to say, where there would not be diffusion of 
bicarbonate from the blood to the lumen. 
This was achieved in the guinea-pig by perfusing the 
duodenal lumen with 24 mmol/1 NaHco3 solution with added 
NaCl for isotonicity. 
There has been considerable controversy in the 
literature regarding the amount of bicarbonate secreted 
actively by the duodenum, versus the quantity that diffuses 
passively from blood to lumen (Flemstrom 1987, Schiessel et 
al. 1984, Simson et al. 1981a). Most of the previous 
experiments on stimulation of duodenal bicarbonate secretion 
in intact animals were performed in the presence of a huge 
blood-to-lumen bicarbonate concentration gradient across the 
duodenal epithelium, while in vitro studies as in the Ussing 
chamber utilized a bicarbonate-free "luminal solution" and a 
bicarbonate-rich "serosal solution" (Simson et al. 1981a, 
Flemstrom & Garner 1982, Flemstrom et al. 1982a, Flemstrom 
et al. 1985, Garner et al. 1990). 
The present guinea-pig model, based on Odes et al. 
(1990) and Heylings & Feldman (1988), was designed to 
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exclude passive diffusion of bicarbonate and permit the study 
of active transport of this anion into the duodenum. Since 
the concentration of bicarbonate in the luminal perfusate was 
about 3 mmol/1 higher than that in the guinea-pig blood, 
uphill transport of bicarbonate against its chemical 
concentration gradient was examined. 
While this model cannot exclude other gradients, such as 
electrical potential differences, or possible slight lumen-
to-tissue diffusion of bicarbonate, passive diffusion of 
bicarbonate from the blood into the lumen is very unlikely. 
The present model appears to answer the need for an active 
secretion set-up in vivo. 
Our finding, that duodenal bicarbonate secretion in the 
guinea-pig involves active transport processes, is in 
accordance with findings in man, where duodenal bicarbonate 
secretion could be stimulated by HCl and PGE2 in the presence 
as well as the absence of a bicarbonate concentration 
gradient (Odes et al. 1990, Knutson et al. 1992). 
It is now known that the duodenum secretes approximately 
equal amounts of bicarbonate, irrespective of whether the 
luminal perfusate contains isotonic NaCl (Flemstrom 1987), 
equimolar bicarbonate (Heylings & Feldman 1988, Odes et al. 
1990) and hypermolar bicarbonate (Odes et al. 1990, and this 
study). 
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WHICH PART OF THE DUODENUM SECRETES BICARBONATE? 
Since bicarbonate secretion decreases in the distal 
duodenum (Isenberg et al. 1983, Isenberg et al. 1986), the 
duodenal segment studied was sited as close to the bulb as 
possible in these studies. The bile duct enters the duodenum 
of the guinea-pig immediately distal to the pylorus, and the 
perfused segment began at that point. The area studied 
therefore corresponded closely to the part of the duodenum 
which in man is afflicted by peptic ulceration. 
The proximal portion of the guinea-pig duodenum 
contains small numbers of Brunner's glands (Fig. 2). Our 
intention was to study mucosal bicarbonate secretion. 
Fortunately, there is quite convincing evidence that 
Brunner's glands do not secrete bicarbonate. Secretin, which 
stimulates Brunner's glands, did not increase basal duodenal 
bicarbonate secretion in another study (Hogan & Isenberg 
1991) and in our study. The distal mammalian (Flemstrom 
1987) and proximal amphibian (Simson et al. 1982) duodenum, 
which are devoid of any Brunner's glands, do secrete 
bicarbonate. The bicarbonate secretion attributed to 
Brunner's glands in a previous study by Kirkegaard et al. 
(1984) was likely derived from the duodenal mucosa. 
We conclude from these observations that in our 
experiments we tested mucosal secretion of bicarbonate. 
However, to finally resolve this controversial issue, it 
will be necessary to devise the methodology whereby viable 
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duodenal mucosa, stripped of all Brunner's glands, can be 
mounted and tested for bicarbonate secretion in Ussing-type 
chambers. 
AGONISTS OF BICARBONATE SECRETION 
Selection of Agonists for these Studies: 
The agonists of duodenal bicarbonate secretion, that 
were examined in these studies, were selected according to 
reports in the literature (Table 1), with the addition of 
TPA, which was not tested before. 
PGE 2 and VIP were selected for study, since they appear 
to be the chief mediators of acid-induced bicarbonate 
secretion. Physiological doses of hydrochloric acid entering 
the duodenum release both mucosal VIP and PGE2 into the 
blood and lumen, increasing duodenal bicarbonate secretion 
in a variety of preparations in vivo and in vitro (Simson et 
al. 1981b, Flemstrom et al. 1982, Flemstrom et al. 1985, 
Odes et al. 1990, Smedfors et al. 1990). Prostanoid 
synthesis was demonstrated in the duodenal submucosa, while 
degradation occurred predominantly in the epithelial cells 
(Smith et al. 1987). Furthermore, in histochemical studies, 
VIP-containing nerve fibres were demonstrated in the lamina 
propria of the mucosa, forming networks around the crypts 
and extending up in the cores of the villi (Larsson et al. 
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1976). These findings indicate the participation of both 
PGE 2 and VIP in the regulation of the secretory s
tatus of 
the mucosal epithelium. Therefore, these agonists were given 
special emphasis in the present study. 
Carbachol was studied because of the profound effect of 
vagal stimulation on bicarbonate secretion (Ballesteros et 
al. 1991, Granstam et al. 1987, Konturek & Thor 1987, Lenz 
et al. 1989, Nylander et al. 1987, Safsten & Flemstrom 
1986). 
Glucagon and secretin, which belong to the VIP "family" 
of peptides, were also tested. The importance of glucagon as 
an agonist of bicarbonate secretion was uncertain. Glucagon 
inhibited basal, secretin- and CCK-stimulated pancreatic 
bicarbonate secretion (Owyang 1991). Secretin, however, is 
the major agonist of pancreatic bicarbonate secretion 
(Schulz 1987). 
Since PGE 2 , VIP, secretin and glucagon act via the 
adenylate cyclase and protein kinase A cascade, dBcAMP and 
theophylline were selected for study. Carbachol however has 
a different action involving protein kinase c. TPA and PGF2u 
act much like carbachol. Therefore, dBcGMP was also studied. 
It should be clear however that these intracellular cascades 
are probably interconnected for many ligands. For example, 
secretin stimulates cyclic AMP and inositol triphosphate 
production in rat pancreatic acinar tissue by two fully 
independent mechanisms (Trimble et al. 1987). 
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Dose-Response Data with Selected Agonists: 
We have demonstrated that dBcAMP, VIP, PGE 2 , carbachol, 
TPA, theophylline, dBcGMP, PGF2a and glucagon stimulate 
duodenal bicarbonate secretion against a bicarbonate 
gradient, this representing active secretion. Secretin was 
not effective as a stimulant (Fig. 3). 
The results show clearly that both the adenylate 
cyclase/cAMP/PKA cascade (stimulated by dBcAMP, theophylline, 
VIP, glucagon and PGE2), and the inositol phospholipid/PKC 
cascade (stimulated by dBcGMP, carbachol, TPA, and PGF2a) 
were involved in secretion of bicarbonate by the duodenum. 
These agents differ in their potency to stimulate 
bicarbonate secretion (although it should be noted that 
dBcAMP was given intraduodenally, and the others i.v.), but 
this was not dependant on the identity of the intracellular 
messengers. 
The most potent agonists, on a molar basis, were dBcAMP, 
VIP, PGE2 and carbachol (Table 2). TPA appeared to be equally 
potent, but a direct comparison is impossible, since TPA was 
tested only in the dose of 10-7 mol/kg. Theophylline was 
intermediate in its effectiveness. Glucagon and dBcGMP were 
weaker stimulants of bicarbonate secretion. Thus, these 
results represent the first direct comparison of the various 
agents, using the same animal and experimental protocol, and 
demonstrate that the agonists can increase bicarbonate 
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secretion in the face of a concentration gradient, so that 
diffusion of bicarbonate is not being measured. 
Yao et al. (1993) showed in rabbit duodenum, maintained 
in a chamber in vitro, that VIP was much more potent (about 2 
log units) than PGE2, theophylline and dBcAMP, in that order. 
Rapid in vivo degradation of VIP would explain the "greater" 
potency of VIP in Yao's work compared to our study in the 
guinea-pig. Also, Yao's luminal perfusate was unbuffered, 
while bicarbonate (25 mmol/1, pH 7.4) was present on the 
serosal side and diffusion of bicarbonate was not prevented. 
Of note, the rabbit duodenum requires pre-treatment with 
indomethacin to depress prostaglandin synthesis and reduce 
the high resting rate of bicarbonate secretion. 
Effect of Combinations of Agonists: 
These studies (Tables 3 to 9), designed to pin-point 
which internal messengers activate bicarbonate secretion, 
yielded most interesting data. Agonists (in submaximal doses) 
utilizing the same, or different, intracellular messengers 
were infused together. The results show that combining 
agonists using different intracellular pathways leads to 
increased (roughly summative) secretion of bicarbonate. 
Combining agonists using identical intracellular pathways, 
however, leads to decreased secretion of bicarbonate. 
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The first result was anticipated, since the doses of 
the agonists in each pair would on their own produce 
submaximal production of duodenal bicarbonate, and further 
secretion of bicarbonate was therefore possible. 
The reason for the second result, the lack of an 
additive effect when two agents acting on the same 
intracellular messenger were combined, is not clear. Several 
lines of reasoning were considered. 
There appeared to be no extraintestinal causative 
factor, such as, for, example, a reduction of systemic blood 
pressure when VIP and PGE2 were given together; however, 
intraduodenal blood flow was not measured, and might have 
been altered by these potent "vasoactive" agents, thus 
affecting generation of bicarbonate. A more likely 
possibility relates to interactions at the receptors at the 
duodenal enterocytes. Could there have been interactions at 
the cell membrane, where one agonist (example: VIP) 
prevented another agonist (like: PGE2 ) from activating its 
receptor, so that bicarbonate secretion decreased? Yet 
another, related explanation refers to "negative" 
interactions of second messenger proteins within the 
duodenal enterocytes. The true reason is not known, and 
awaits further experimental study. 
It is interesting that a very similar phenomenon was 
noted by Yao et al. (1991), who studied stimulated 
bicarbonate secretion in the rabbit duodenum mounted in the 
ussing chamber. Yao et al. found that when dBcAMP was 
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combined with VIP or PGE 2 , the bicarbonate secretion was 
less than when dBcAMP was used alone as a stimulant. 
Further, the combination of VIP and PGE 2 stimulated less 
bicarbonate secretion than either agonist on its own. These 
data are similar to our own and suggest immediately that 
tissue blood flow cannot be the explanation. As stated 
above, the answer must lie in receptor or post-receptor 
phenomena in the duodenal enterocytes. 
The data presented here, and those of Yao et al. 
(1991), could have distinct physiological consequences, 
since they clearly imply that bicarbonate secretion is 
reduced when certain compounds (utilizing identical 
intercellular messengers) stimulate the duodenum in unison. 
This could be important especially in the case HCl-induced 
physiological bicarbonate secretion, which, as indicated 
above, is mediated jointly by VIP and PGE 2 • 
Cyclic AMP as the Second Messenger of PGE 2 and VIP: 
The demonstration that dBcAMP stimulates duodenal 
bicarbonate secretion in vitro (Simson et al. 1981b, Garner 
et al. 1990, Yao et al. 1991) implies participation of cAMP 
as a second messenger in stimulated bicarbonate secretion. 
This however still had to be proved. For this reason, we 
tried to mimic the effects of PGE 2 and VIP on duodenal 
bicarbonate secretion by using intraduodenal dBcAMP, and we 
measured cAMP production in duodenal enterocytes exposed to 
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VIP, PGE 2 and other agonists (in a collaborative study with 
Dr. R Reimer, Germany). 
VIP and PGE2 , which concentration-dependently increased 
active duodenal bicarbonate secretion in our in vivo model, 
stimulated adenylate cyclase of homogenates prepared from 
isolated duodenal epithelial cells. By contrast, secretin 
and PGF2a, showing no or little effect on bicarbonate 
secretion, stimulated adenylate cyclase to a considerably 
lesser extent than VIP and PGE2 (Reimer et al. in press). 
The increased intracellular cAMP levels in duodenal 
epithelial cell homogenates were next followed by an 
increase in the activity of protein kinase A. Timewise, 
these increases preceded the rise in duodenal bicarbonate 
secretion as was detected in the guinea-pig perfused 
duodenal segment in vivo. These events followed each other 
in a way that is likely for coupled processes; at the time 
the preceding stimulus reaches its maximum, the following 
event shows its steepest slope (Fig. 6). These observations 
fulfill the criteria of Sutherland (1968) for establishing 
that cAMP mediates intestinal secretion. 
our conclusion is that VIP and PGE2 stimulate active 
bicarbonate secretion in the guinea-pig duodenum via 
increases in intracellular cAMP and protein kinase A. 
This theory is supported by several studies. Garner et 
al. (1990) stimulated duodenal bicarbonate secretion, in 
vivo and in vitro, with the phosphodiesterase inhibitors, 
theophylline and IBMX, which raise intracellular cAMP 
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levels. Simson et al. (1981b) stimulated amphibian duodenal 
bicarbonate secretion in vitro by theophylline, and Yao et 
al. (1991) found a similar effect of dBcAMP and theophylline 
in the rabbit duodenum in vitro. VIP and PGE2 are known to 
act via receptors coupled to stimulation of adenylate cyclase 
in isolated enterocytes in the rat (Nakaki et al. 1983) and 
guinea-pig (Binder et al. 1980); this has now been shown in 
the human as well (Smith et al. 1990). By contrast, the high 
doses of secretin required for stimulation of adenylate 
cyclase in vitro (Reimer et al. in press) indicate a 
pharmacological response, and are consistent with the lack of 
effect of this hormone on bicarbonate secretion in the 
guinea-pig in vivo (Fig. 4). Glucagon did not stimulate 
adenylate cyclase; it appears to be a weak stimulant of 
duodenal bicarbonate secretion and it could be acting via 
another mediator (as shown for carbachol, see above). 
Receptors for VIP in the Guinea-Pig Duodenal Enterocytes: 
Stimulation of active transport processes necessarily 
involves the activation of specific transport systems via 
intracellular signalling mechanisms. 
We have recently reported the presence of receptors for 
VIP (Reimer et al. 1993b) on duodenal epithelial cells, which 
are coupled to stimulation of adenylate cyclase. In that 
study, VIP stimulated adenylate cyclase in homogenates 
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of duodenal epithelial cells with a more than 1000-fold 
higher potency than secretin. 
These results agree well with the results of receptor 
binding studies by Binder et al. (1980), where secretin was 
shown to be 1000-fold less potent than VIP in inhibiting 
binding of radiolabeled VIP in the guinea-pig small 
intestine. This argues for the presence of a VIP-receptor on 
duodenal epithelial cells. 
These in vitro data of Binder et al. (1980) correspond 
well with the physiological response in the present study, 
where the neuropeptide VIP (10-9 mol/kg) stimulated 
bicarbonate secretion 3-fold in the perfused guinea-pig 
duodenal segment (Fig. 3 and 4), while the structurally 
related hormone secretin, in the same dose (10-9 mol/kg), 
was ineffective in stimulation of duodenal bicarbonate 
secretion (note that in this dose, secretin was a powerful 
agonist of pancreatic bicarbonate secretion). 
We can now hypothesize that binding of VIP to its 
receptors, which are located on basolateral membranes 
(Dharmsathaphorn et al. 1983), causes activation of 
adenylate cyclase, also located in basolateral membranes 
(Murer et al. 1976), which then leads to the formation of 
cAMP in duodenal enterocytes. This then is the process 
whereby VIP induces active duodenal bicarbonate secretion in 
the guinea-pig. 
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Receptors for Prostaglandins in the Guinea-Pig Duodenal 
Enterocytes: 
Recently, our group published that this prostanoid 
receptor is of the EP 2-subtype (Reimer et al. 1992). PGE 2 
binds with high affinity to this type of receptor (Coleman 
et al. 1990). Specific prostanoid binding was shown in rat 
small intestinal preparations by Wu-Wang et al. (1989). 
Coupling of the prostanoid receptor to adenylate cyclase was 
demonstrated by Smith et al. (1987). 
PGF2a is known to have a very low affinity f
or EP 2-
receptors. This is confirmed by our finding that stimulation 
by PGF2a of adenylate cyclase was very small. O
ur finding 
that PGF2a can stimulate duodenal bicarbonate sec
retion, 
although to a lesser extent than PGE 2 , indicates the 
involvement of other effects than increases in intracellular 
cAMP levels in PGF2a-stimulated duodenal bicarbonate 
secretion, and implies that other cellular pathways are 
working. 
The Link with Protein Kinase A: 
In all systems in which the effect of cyclic AMP is 
understood, adenylate cyclase-cyclic AMP induced activation 
of proteins results from changes in regulation of 
phosphorylation/dephosphorylation. Cyclic AMP activates 
CAMP-dependent protein kinases by binding to the regulatory 
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subunit and release of the catalytic subunit (Gettys & 
Corbin 1989). We have reported (Reimer et al. 1991) that 
upon stimulation of duodenal cells with VIP and PGE 2, the 
soluble (cytosolic) PKA activity increased, while the total 
amount of PKA in the particulate fraction decreased, 
indicating a translocation from the membranes to the 
cytosol. 
The cAMP effect on intestinal transport is likely to 
occur directly at the brush border membrane. Phosphorylation 
of specific membrane proteins by CAMP-dependent protein 
kinases was shown for the rat small intestine (de Jonge 
1976, Shlatz et al. 1978). In addition, Dunk et al. (1989) 
showed that incubation of rat duodenal brush border membrane 
vesicles with cAMP and ATP stimulated c1-/Hco3- exchange by 
a cAMP-dependent protein kinase. Since both cAMP and the 
catalytic subunit of protein kinase A are soluble, 
activation of basolateral membrane adenylate cyclase can 
lead to activation of CAMP-dependent proteins throughout the 
cell. Although the highest PKA activity was recovered in the 
cytosolic fraction, large amounts were found in the 
particulate fraction. This is in agreement with findings in 
membrane preparations of intestinal epithelial cells, where 
cAMP-dependent protein kinase activity could be detected in 
basolateral and brush border membranes (Shlatz et al. 1978). 
In addition, histochemical studies showed high cAMP binding 
to basolateral membranes, indicating the presence of 
intracellular, membrane-bound receptors for cAMP (Ong et al. 
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1975). Other polarized cells like proximal and collecting 
duct epithelial cells also showed a high amount of cAMP-
dependent protein kinases in plasma membranes (Kinne et al. 
1975). This could be the basis for a spatial model 
explaining how VIP and PGE 2 activate duodenal bicarbonate 
secretion. 
CHOLINERGIC REGULATORY MECHANISMS 
In our detailed studies of the cholinergic regulation 
of duodenal bicarbonate secretion in the guinea-pig, there 
were three main findings: 
(i) The cholinergic agonist carbachol stimulates 
bicarbonate secretion by the m-cholinoceptor pathway. 
(ii) Carbachol-stimulated bicarbonate secretion is not a 
direct effect but proceeds via the neuropeptide hormone VIP, 
and the lack of demonstrable receptors for carbachol on 
isolated duodenal enterocytes is consistent with this 
observation. 
(iii) The cholinergic pathway is dependent on the presence 
of intracellular ca2+. 
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Muscarinic Effects: 
While central vagal stimulation increases duodenal 
bicarbonate secretion (Ballesteros et al. 1991, Flemstrom & 
Jedstedt 1989, Konturek & Thor 1987, Lenz & Forquignon 1990, 
Lenz et al. 1989), carbachol, bethanechol and atropine have 
shown inconsistent and weak effects on basal and stimulated 
duodenal bicarbonate secretion (Ballesteros et al. 1991, 
Granstam et al. 1987, Hogan & Isenberg 1991, Konturek & Thor 
1987, Lenz et al. 1989, Smedfors & Johansson 1986, Takeuchi 
et al. 1989, Takeuchi et al. 1990). This could have been the 
result of species differences, but has given the impression 
that cholinergic stimulation is less important than that of 
prostaglandins and VIP. 
We differ from these reports by demonstrating here that 
carbachol is a potent stimulant of bicarbonate secretion in 
the guinea-pig, and that atropine and pirenzepine inhibit 
basal and carbachol-stimulated bicarbonate secretion. 
On a weight basis, the relative inhibitory potency of 
parenteral atropine to pirenzepine on exocrine glands is 
1:10 (Jaup 1981). The doses of pirenzepine and atropine that 
produced similar inhibition of carbachol-stimulated 
bicarbonate secretion were in the same ratio. 
While this suggests that the cholinergic pathway for 
bicarbonate secretion is of the m1-cholinoceptor type, 
additional studies with specific m2- and m3-cholinoceptor 
antagonists are required to finalize this issue. A previous 
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report that carbachol requires an m2-cholinoceptor pathway, 
was based only on the failure of pirenzepine to inhibit 
carbachol-stimulated bicarbonate secretion (Takeuchi et al. 
1990), and appears to be premature. 
The present results with pirenzepine, which inhibited 
bicarbonate secretion, cannot be reconciled with previous 
observations in the rat that this agent stimulated duodenal 
bicarbonate secretion (Safsten & Flemstrom 1986, Takeuchi et 
al. 1990). The reason for this discrepancy is not apparent. 
Nicotinic Effects: 
Since hexamethonium also reduced carbachol-stimulated 
duodenal bicarbonate secretion, a role for a non-muscarinic 
cholinergic transmitter is possible. 
Hexamethonium also inhibited the effect of vagal 
stimulation on duodenal bicarbonate secretion in rat 
(Fandriks et al. 1991), while atropine only partially 
inhibited the bicarbonate response to sham feeding in man 
(Ballesteros et al. 1991). Hexamethonium, but not atropine, 
inhibited the prostaglandin E2-mediated bicarbonate 
secretion which followed duodenal acidification (Smedfors et 
al. 1990). 
The substantial hypotension following the injection of 
hexamethonium, however, could itself depress the secretion 
of bicarbonate, via stimulation of the alpha2 adrenoceptors 
(Fandriks et al. 1991). Indeed, we observed a brisk return 
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of carbachol-stimulated duodenal bicarbonate secretion once 
the blood pressure rose. Therefore, our results with 
hexamethonium, as well as those of earlier workers, do not 
allow of any firm conclusion regarding an n-cholinoceptor 
transmitter in duodenal bicarbonate secretion. 
VIP as a Cholinergic Mediator of Bicarbonate Secretion: 
VIP is an agonist of duodenal bicarbonate secretion 
(Flemstrom et al. 1985, Algazi et al. 1989, Wolosin et al. 
1989). Our observations with the VIP-antagonist support the 
notion that the cholinergic pathway to bicarbonate secretion 
is largely mediated via VIP. 
Of note, pirenzepine had no effect on VIP-mediated 
bicarbonate secretion. Unlike Smedfors et al. (1987), we did 
show partial atropine-inhibition of VIP-stimulated 
bicarbonate secretion; the mechanism of this action is not 
clear. We have reported that specific VIP receptors exist on 
duodenal mucosal cells (Reimer et al. 1993b); therefore, the 
"presence" of another mediator after VIP would mean that an 
unidentified intracellular agent (protein) is involved, or 
that there are different cell populations among the duodenal 
enterocytes. This issue needs to be resolved. 
Smedfors et al. 1987 and Algazi et al. (1989) found 
that HCl-stimulated duodenal bicarbonate secretion is 
mediated by VIP. We showed that basal bicarbonate output too 
requires some VIP activity. [D-p-Cl-Phe6,Leu17] VIP as well 
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as atropine blocked the stimulatory effect of intracerebral 
somatostatin on rat duodenal bicarbonate secretion (Lenz & 
Forquignon 1990), which is in keeping with our finding that 
VIP acts as a cholinergic neurotransmitter in the duodenum. 
By comparison, prostaglandin-stimulated duodenal bicarbonate 
secretion is independent of the action of VIP (Algazi et al. 
1989), and not affected by atropine (Smedfors et al. 1990) 
or by pirenzepine, as we have shown here. 
Role of Intracellular Calcium: 
We studied the role of calcium in stimulus-secretion 
coupling associated with carbachol-induced bicarbonate 
secretion. 
Verapamil abolished carbachol-stimulated bicarbonate 
secretion, as was described previously (Takeuchi et al. 
1990), as well as basal bicarbonate secretion. A similar 
effect on bicarbonate secretion was detected with the more 
specific calcium channel blocker, nifedipine. This shows 
that ca2+ is required for cholinergically stimulated 
bicarbonate production in the duodenum. 
This notion is further supported by our finding that 
A23187 dose-dependently stimulated basal bicarbonate 
secretion, and modestly but significantly augmented the 
effect of carbachol when these two agents were combined. 
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A23187 also stimulated amphibian duodenal bicarbonate 
secretion in vitro (Simson et al. 1982). 
The site of action of A23187 appears to be proximal to 
the duodenal enterocytes which carry VIP receptors, since 
the VIP antagonist blocked A23187-stimulated duodenal 
bicarbonate secretion. It appears that calcium is required 
for the cholinergic release of VIP, the mediator of 
carbachol-induced bicarbonate secretion, and that verapamil 
and nifedipine may act to prevent release of VIP after 
carbachol stimulation. 
Whether cholinergic stimulation releases mediators 
other than VIP, as well is not known, but the lack of effect 
of indomethacin on carbachol-stimulated bicarbonate 
secretion in the present and a previous study (Takeuchi et 
al. 1990) does indicate that the ca2+-mediated pathway is 
independent of endogenous prostaglandin synthesis. 
Taken together, the results show that carbachol-
stimulated duodenal bicarbonate secretion is mediated by m-
cholinoceptors, vasoactive intestinal peptide and calcium. 
Calcium has a role in mediating bicarbonate secretion both 
in the basal state (resting vagal tone) and after 
cholinergic stimulation. 
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Receptors for Carbachol in the Guinea-Pig Duodenal 
Enterocytes: 
In our studies, as reported by Reimer et al. (1993a), 
there was a virtual absence of 3H-N-methylscopolamine binding 
and a failure of the intracellular ca2+ concentration to 
increase in response to carbachol stimulation of isolated 
duodenal enterocytes. This indicates that the duodenal 
enterocytes contain very few m-cholinoceptors and that 
carbachol stimulation of ~uodenal bicarbonate secretion 
requires an intermediate messenger. We have shown that this 
is VIP. 
Postulated Cholinergic Pathway: 
Our postulates of the pathway involved in the 
cholinergic stimulation of duodenal bicarbonate secretion are 
shown schematically in Fig. 18. 
The uncertainties in this pathway relate to the role, if 
any, of n--cholinoceptors, and the meaning of inhibition of 
VIP by atropine (the "post-VIP" ligand). These issues require 
further investigation. 
However, it should be understood that the adenylate 
cyclase-protein kinase A cascade is not the only 
intracellular messenger of bicarbonate secretion, even if it 
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appears to mediate cholinergic secretion (from the role 
described herein for VIP). We have found a clear response to 
stimulation with TPA, demonstrating that protein kinase C is 
involved in bicarbonate secretion as well (Odes et al. 
1992). Furthermore, atropine partly inhibited the action of 
VIP. The pathways involved are certainly more complex than 
is presently known. 
128 
FIGURE 18. Proposed pathway of the cholinergic regulation 
of guinea-pig duodenal bicarbonate secretion. The 
cholinergic stimulus activates the m1-cholinoceptors (m1 ), 
and possibly also the m2-cholinoceptors (m2), located on 
VIP-secreting cells situated in close proximity to vagal 
nerve terminals in the duodenum. The role of then-
cholinoceptor (n) is not clear, given the hypotensive effect 
of hexamethonium in our experiments. VIP production or 
secretion requires calcium entry via nifedipine-sensitive 
channels, since the VIP- antagonist [D-p-Cl Phe6,Leu17]-VIP 
inhibited the effect of the calcium ionophore A23187. VIP in 
turn activates VIP-receptors presumed to be present on 
duodenal mucosal cells that secrete bicarbonate. The 
mechanism of atropine-inhibition of VIP-stimulated 
bicarbonate secretion requires elucidation; pirenzepine had 
no such effect. Note that the bold arrows indicate 
stimulation and the thin arrows indicate inhibition of 
secretion. 
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ROLE OF SOMATOSTATIN IN DUODENAL BICARBONATE SECRETION 
The present experiments examined the influence of 
somatostatin-14 on guinea-pig duodenal bicarbonate 
secretion. 
Effect on Basal and Stimulated Bicarbonate Secretion: 
The depressant action of somatostatin on basal duodenal 
bicarbonate secretion in our study is consistent with the 
general inhibitory effects of this hormone in the 
gastrointestinal system (Yamada & Chiba 1989). 
Certain earlier studies are at variance with our data. 
The lack of effect of somatostatin on basal bicarbonate 
secretion by frog duodenal mucosa in vitro (Flemstrom et al. 
1982a) could possibly be explained by the already low basal 
bicarbonate secretion rate in that model. The failure of 
i.v. somatostatin-14 to reduce basal duodenal bicarbonate 
secretion in the conscious rat (Lenz & Forquignon 1990) is 
however difficult to explain since the same dose (lo-11 
mol.kg-1) was effective in the present experiments (Fig. 
12). Somatostatin-14 inhibited basal bicarbonate output in 
the anaesthetized rat by decreasing the volume of duodenal 
secretion (Kirkegaard et al. 1984). Of note, somatostatin-28 
is not an agonist of duodenal bicarbonate secretion (Lenz & 
Forquignon 1990). 
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It is of interest that somatostatin inhibited both 
carbachol-stimulated and VIP-stimulated duodenal bicarbonate 
secretion. Cassuto et al. (1983) showed that in the process 
of intestinal secretion, a VIP-ergic neuron is situated 
distal to the cholinergic neuron. Lenz et al. (1989) 
reported that TRH-induced vagal stimulation of duodenal 
bicarbonate secretion is mediated by cholinergic pathways 
and VIP. we have demonstrated (the present study, and Odes 
et al. in press) that carbachol, at least in part, exerts 
its effect on duodenal bicarbonate secretion via the release 
of VIP. In the guinea pig-ileum, somatostatin hyperpolarizes 
almost exclusively neurons immunoreactive for VIP, and in 
this way inhibits the release of VIP (Cooke 1989). 
Therefore, somatostatin may inhibit carbachol-stimulated 
bicarbonate secretion by an action related to VIP. This 
postulated effect of somatostatin on VIP could also explain 
the inhibitory effect of somatostatin on basal bicarbonate 
secretion, a process that is largely under vagal control 
(Ballesteros et al. 1991). Kirkegaard et al. (1984) too 
showed that somatostatin decreased VIP-stimulated 
bicarbonate secretion in rat duodenum in vivo. 
VIP and PGE 2 both stimulated adenylate cyclase activity 
in the present study. We have reported that VIP and PGE2 act 
via distinct receptors on duodenal epithelial cells, 
increasing intracellular cAMP by activation of adenylate 
cyclase (Reimer et al. in press, Reimer et al. 1993b). In 
the amphibian and mammalian duodenum, an increase in 
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intracellular cAMP by phosphodiesterase-inhibitors led to 
increased bicarbonate secretion (Garner et al. 1990). While 
somatostatin inhibited VIP-stimulated bicarbonate secretion, 
it did not inhibit adenylate cyclase. Furthermore, PGE2-
stimulated bicarbonate secretion was not affected. These 
findings, taken together, appear to indicate that 
somatostatin does not act directly at the duodenal 
enterocytes. 
The inhibitory effect of somatostatin on VIP-stimulated 
bicarbonate secretion is best explained by postulating that 
somatostatin prevents the release by VIP of another mediator 
(possibly cholinergic) which then stimulates bicarbonate 
secretion. In support of this hypothesis is our finding that 
VIP-stimulated duodenal bicarbonate secretion is partly 
atropine-sensitive (Odes et al. in press). 
Our present understanding of the role of somatostatin-
14 in regulating duodenal mucosal bicarbonate secretion is 
illustrated in Fig. 19. 
Activity of Somatostatin in Duodenal Enterocytes: 
Molecular cloning has revealed the presence of four 
high-affinity somatostatin receptors (SSTR) acting on 
specific intracellular signalling systems. This includes the 
SSTRl receptor in the upper small intestine, whose effector 
system is apparently not coupled to adenylate cyclase (Bell 
& Reisine 1993). 
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This is in keeping with the lack of effect of 
somatostatin on duodenal enterocyte cAMP production in the 
present study. It is not likely that this phenomenon is the 
result of damage caused to the somatostatin receptor in the 
cell homogenization process, since the receptors of VIP and 
PGE 2 were functional in our preparations of duodenal 
enterocytes. It remains possible that intracellular 
mediators other than cAMP are coupled to the somatostatin 
receptor in the duodenum. However, since we did not detect 
cholinoceptors on guinea-pig duodenal enterocytes (Reimer, 
1993), the effect of somatostatin on protein kinase C and 
intracellular ca2+ was not examined in the present study. 
Immunity of PGE 2 to the Effects of Somatostatin: 
Cholinergic stimulation to the upper gastrointestinal 
tract has multiple physiological effects. There is release 
of acid in the stomach (Isenberg et al. 1991), and release 
of PGE 2 (Bukhave et al. 1990), VIP (Smedfors et al. 1987) 
and somatostatin (Fujimiya et al. 1992) in the duodenum. 
PGE 2 amplifies duodenal bicarbonate secretion independently 
of VIP (Algazi et al. 1989). VIP, as shown, is not effective 
in the presence of somatostatin. Of note, PGE 2 levels may be 
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FIGURE 19. Postulated mechanism of action of somatostatin 
on duodenal Hco3- secretion. Carbachol, which did not 
stimulate mucosa! adenylate cyclase, stimulates duodenal 
HCo3- secretion via VIP. It is postulated that VIP releases 
an unidentified, possibly cholinergic, mediator that is inhibited by somatostatin at a site proximal to the duodenal 
enterocyte, since cyclic AMP production is unaltered by 
somatostatin. PGE2 stimulates cAMP formation in the duodenal 
enterocytes and this action is not affected by somatostatin. 
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increased in the inflamed duodenum. Therefore, it is 
conjectured that the "immunity" of PGE2 to the effects of 
somatostatin-14, as shown by the present data (Fig. 14), may 
constitute a protective mechanism in the acidified duodenum. 
The action of PGE2 in stimulating bicarbonate secretion, an 
action insensitive to somatostatin, is an important duodenal 
defence mechanism; thus, antiinflarnmatory drugs like 
indomethacin, which inhibit PGE2 synthesis, are ulcerogenic. 
In summary, the present study has shown a role, best 
described as "selective", for somatostatin-14 in the 
regulation of duodenal bicarbonate secretion. The precise 
pathways involved require further investigation. 
ROLE OF CARBONIC ANHYDRASE IN DUODENAL BICARBONATE SECRETION 
These studies have shown that carbonic anhydrase is 
required for active bicarbonate transport under basal 
conditions, and for active bicarbonate secretion stimulated 
by dBcAMP, dBcGMP, PGE2, PGF2o, TPA, glucagon, VIP and 
carbachol. It was shown that carbonic anhydrase is 
distributed equally in crypt and villus cells in the guinea-
pig duodenum. 
Duodenal Carbonic Anhydrase and Bicarbonate Secretion: 
The duodenum contains one tenth the carbonic anhydrase 
of the gastric antrum in the rat; in both organs the enzyme 
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is located largely in the cytosol (Stiel et al. 1984, and 
our own study). 
Studies of the function of carbonic anhydrase in 
duodenal bicarbonate secretion have yielded conflicting 
data. 
Thus, acetazolamide had a variable effect on 
bicarbonate secretion by the bullfrog duodenum in vitro, 
with a high dose being required to produce mild inhibition 
(Flemstrom 1980, Simson et al. 1981a). This is consistent 
with the notion that low rates of bicarbonate secretion, as 
in the bullfrog in vitro, do not require carbonic anhydrase. 
In the rat, the drug did not reduce basal bicarbonate 
secretion (Flemstrom & Kivilaakso 1983, Takeuchi et al. 
1986); the effect on PGE2- and PGF2a - stimulated secretion 
was either inhibitory (Flemstrom & Kivilaakso 1983, Isenberg 
et al. 1983) or negligible (Takeuchi et al. 1986). In the 
rabbit, where resting bicarbonate secretion is high (the 
result of a high basal prostaglandin synthesis), 
acetazolamide reduced basal bicarbonate secretion (Holm et 
al. 1990). Like the rabbit, the guinea pig has a high basal 
bicarbonate secretion rate too (Flemstrom et al. 1982a), 
which is due to a high basal prostaglandin synthesis; 
therefore, in the present study the animals were pre-treated 
with indomethacin to reduce this background stimulation. 
Carbonic anhydrase seemingly cannot be stimulated by 
agonists. we have found (Odes & Reimer, preliminary 
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observations), that incubation of isolated duodenal cells 
with three potent agonists of bicarbonate secretion, PGE2 , 
VIP or carbachol did not show any increase in the activity 
of carbonic anhydrase enzyme. 
Source of Bicarbonate: 
The mechanisms of transport of bicarbonate to the gut 
lumen are not clearly understood. There is evidence that 
bicarbonate can be transported to the duodenal lumen both 
transcellularly and paracellularly, by serosal co2- and 
Hco3--dependent processes (Flemstrom 1980, Simson et al. 
1981a); similar observations were made in the distal colon 
(Rho et al. 1991). In the frog duodenum in vitro there was 
considerable paracellular diffusion of co2 which accounted 
for 40% of bicarbonate secretion, and little endogenous 
generation of Hco3- by carbonic anhydrase (Simson et al. 
1981a). In the rabbit duodenum exposed to intralurninal acid, 
bicarbonate transport appeared to be passive (Vattay et al. 
1988, Vattay et al. 1989). By contrast, acetazolarnide 
decreased basal, PGE 2 and HCl-stimulated bicarbonate 
secretion in the human duodenum (Knutson et al. 1992). 
Unlike previous workers using rodents, we have shown 
significant decreases of basal and stimulated bicarbonate 
secretion in the presence of acetazolarnide, regardless of 
the absolute secretory rate. This suggests that the secreted 
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bicarbonate, at least in part, is generated intracellularly 
by carbonic anhydrase-mediated hydration of CO2. 
Our finding that acetazolamide reduced bicarbonate 
secretion in response to a variety of agonists implies that 
carbonic anhydrase, providing a source of bicarbonate, 
functions as a common step in stimulus secretion coupling 
leading to bicarbonate secretion. Carbonic anhydrase may be 
linked to a luminal c1-/HC03- exchanger present in isolated 
duodenocytes (Flemstrom & Garner 1982, Gleeson 1992). 
Other Functions of Carbonic Anhydrase: 
An important consideration in interpreting the action of 
acetazolamide in laboratory experiments relates to the 
ability of this drug to cause acidosis in small animals. The 
dose of acetazolamide employed in the present study however 
is reported to be non-toxic (Lonnerholm et al. 1989). This 
dose did not cause cardiac and respiratory side-effects or 
acidosis in our animals, as shown by the lack of respiratory 
changes and the stability of blood pressure and pulse 
tracings and blood pH (where tested) during the infusion of 
acetazolamide. The absorption of luminal bicarbonate during 
acetazolamide treatment occurred along its concentration 
gradient, possibly by a paracellular pathway, and was not 
caused by acidosis; we observed a similar phenomenon during 
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inhibition of duodenal bicarbonate secretion with 
somatostatin in the current experiments. 
The dose of acetazolamide used here (80 mg/kg) 
calculates to about 3.4 x 10-4 mol/1 in the animal body 
water, sufficient to produce over 99% inhibition of carbonic 
anhydrase (Lonnerholm et al. 1989). In addition to 
inhibiting carbonic anhydrase, acetazolamide in this dose 
could also have inhibited a bicarbonate export mechanism at 
the cell membrane of duodenal epithelial cells. The present 
data do not allow of a conclusion regarding this 
possibility. Hence, the precise function of carbonic 
anhydrase in the duodenum requires further investigation. In 
particular, the relationship between carbonic anhydrase and 
cell membrane exporters or transporters of bicarbonate 
remains to be determined. 
Site of Bicarbonate Secretion along the Duodenal Villus-
Crypt Axis: 
The identity of the duodenal epithelial cells 
responsible for bicarbonate secretion is unknown. It is 
thought that, in the entire small intestine, the crypt is 
secretory and the villus absorptive (Donowitz & Welsh 1987). 
Since the duodenal villi are most exposed to acidic duodenal 
chyme, bicarbonate secretion by the villi would be an 
appropriate defense. 
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The present finding, that carbonic anhydrase is located 
equally in the villi and crypts, may indicate that both 
these areas are sites of bicarbonate secretion. These 
results differ from a previous study by Lonnerholm (1976) in 
guinea-pig jejunum, where staining for carbonic anhydrase 
could be detected in a small number of epithelial cells 
only. These differences are probably due to the less 
sensitive cobalt precipitation technique used by Lonnerholm 
(1976). An immunohistochemical study in the rat showed that 
carbonic anhydrase II, the dominant acetazolamide-sensitive 
isoenzyme in the duodenum, was confined to the villus 
epithelium (Lonnerholm 1989), and this suggested that 
alkaline secretion is of villus origin. This was confirmed 
in the rat jejunum, where it was shown that net secretion in 
the small bowel is probably not confined to the crypts and 
may also occur from villus epithelium (Stewart & Turnberg 
1989). We did not determine which isoenzyme of carbonic 
anhydrase was present in the duodenum of the guinea pig. In 
rat duodenum, carbonic anhydrase II predominates while 
carbonic anhydrase I is scanty (Lonnerholm 1976). 
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Clinical Relevance of Carbonic Anhydrase in Bicarbonate 
Secretion: 
The clinical importance of carbonic anhydrase in 
bicarbonate secretion is not yet properly defined, and has 
been little studied. 
In normal man, acetazolamide (0.5 g/day orally for 2 
days) was shown to reduce PGE 2-stimulated and acid-
stimulated bicarbonate secretion (Knutson et al. 1992). 
Further studies are needed in this area. 
SUMMARY: REGULATION OF DUODENAL BICARBONATE SECRETION 
The guinea-pig duodenal model studied here contained 
many interacting tissues and cells, but had the advantage 
that bicarbonate secretion could be measured directly at all 
times. By complementing these studies with various in vitro 
experiments, a partially comprehensive picture of the 
control of active duodenal bicarbonate secretion is 
beginning to emerge. 
It is clear that dBcAMP, VIP, PGE 2 and theophylline are 
among the chief agonists of duodenal bicarbonate secretion 
in the guinea-pig. All these agonists act through adenylate 
cyclase. Correlation with in vitro data shows that VIP and 
PGE2 act directly via receptors on the duodenal enterocytes, 
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activating adenylate cyclase and protein kinase A in 
sequence to initiate bicarbonate secretion. Theophylline 
and dBcAMP act internally in the duodenal enterocytes. 
Glucagon is a weak agonist of bicarbonate secretion, 
not altering duodenal CAMP production; its physiological 
importance is in doubt. Of note, secretin is not an agonist 
of bicarbonate secretion, although it does have receptors in 
the duodenum. 
Carbachol is a potent agonist of active bicarbonate 
secretion and acts in the m-cholinoceptor pathway. It does 
not act directly on duodenal epithelial cells, but 
stimulates duodenal bicarbonate secretion by releasing VIP. 
Consistent with this finding is the observation that 
carbachol itself has few receptors on duodenal enterocytes. 
It can thus be said that carbachol, working via VIP, also 
utilizes the adenylate cyclase cascade. The cholinergic 
pathway requires intracellular ca2+, perhaps for the release 
of VIP. In contrast to the knowledge obtained about the 
muscarinic pathway, the role of the nicotinic pathway in 
bicarbonate secretion remains uncertain, owing to the 
hypotensive action of hexamethonium. 
There is evidence that the inositol phospholipid and 
protein kinase C cascade are involved in bicarbonate 
secretion, possibly to a lesser extent, since tetradecanoyl-
phorbol-acetate and PGF2 a were agonists of bicarbonate 
secretion. 
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Somatostatin selectively suppresses carbachol-stimulated 
and VIP-stimulated duodenal bicarbonate secretion, but not 
PGE2-stimulated bicarbonate secretion. Receptors for 
somatostatin coupled to adenylate cyclase could not be 
detected on isolated duodenal enterocytes, which strengthens 
the hypothesis that carbachol does not act directly on these 
epithelial cells, but via a second transmitter, which is VIP. 
The irrununity of PGE2 to the actions of somatostatin appears 
to be a protective mechanism. Cholinergic stimulation, as 
during gastric acid secretion, releases VIP, PGE2 and 
somatostatin. VIP may be less effective in stimulating 
bicarbonate production under these conditions, but PGE2 will 
continue to be an agonist of bicarbonate secretion, offering 
protection to the duodenal mucosa which is bathed by HCl. 
Carbonic anhydrase activity is necessary for secretion 
of bicarbonate. Inhibition of this enzyme by acetazolarnide 
decreases basal duodenal bicarbonate secretion and stops the 
stimulation by diverse agonists. Carbonic anhydrase likely 
serves as a corrunon final step in the generation of 
bicarbonate in duodenal enterocytes. Carbonic anhydrase is 
located in the cytoplasm of cells in the villus as well as 
the crypt cells, implying that bicarbonate secretion occurs 
along the length of the villus and crypt. 
In surrunary, the present research has shown direct 
stimulation of duodenal bicarbonate secretion by VIP, which 
participates also in the m-cholinergic pathway, and by PGE2. 
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Adenylate cyclase and protein kinase A appear to be the 
intracellular messengers with the primary function of 
initiating duodenal bicarbonate secretion. However, there is 
convincing evidence that the inositol phospholipid and 
protein kinase C cascade also activates this secretion. 
Somatostatin selectively stops duodenal bicarbonate 
secretion. Carbonic anhydrase activity in the crypt and 
villus is required as the final common step in bicarbonate 
production. 
The findings of this research provide a basis for 
further, more comprehensive studies of bicarbonate secretion 
in the duodenum of man in health and disease. 
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